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ABSTRACT 
GENERATION OF REPORTER CELL LINES BY GENOME EDITING                                        
TO PROBE P53 ACTIVITY 
 
NAZİFE TOLAY 
Molecular Biology, Genetics and Bioengineering, MSc Thesis, July 2018 
 Thesis supervisor: Prof. Batu Erman  
Keywords: p53, TALENs, genome editing, cell-based reporter assay, compound 
screening 
The p53 protein is defined as a sequence-specific transcription factor and functions as a 
tumor suppressor protein. The p53 protein is involved in diverse cellular processes which 
are important for controlling cell cycle arrest and apoptosis. The regulation of p53 is 
governed by an autoregulatory negative feedback loop between p53 and MDM2. 
Mutations in the TP53 gene and defects in the regulation of p53 are mostly associated 
with tumor initiation, invasion, and metastasis. Therefore, restoration of p53 functions to 
target cancer cell viability has been used for cancer therapy. Genome editing techniques 
have been used as an effective method to correct mutations, to integrate a gene of interest, 
and to knock out genes. We generated reporter cell lines by using genome editing methods 
to probe the transcriptional activation of p53. We showed that TALEN induced genome 
editing is an effective method to integrate a reporter gene into a targeted safe harbor site. 
We investigated the effects of various compounds on the transcriptional activity of p53 
by using these reporter cell lines and found that some of these compounds increased the 
transcriptional activity of p53. We also analyzed the effects of the compounds on cell 
viability in either the presence or absence of p53 and we showed that these compounds 
caused cell death independent of p53. Additionally, we identified that all compounds 
stabilized the p53 protein in HCT 116 p53 WT cells. We showed that this stabilization 
was because of damage-induced post-translational modification of p53. Lastly, we 
showed that these compounds did not block the interaction between MDM2 and p53. In 
summary, we developed and tested screening tools to identify modifiers of p53. 
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ÖZET 
P53’ÜN AKTİVİTESİNİ ARAŞTIRMAK İÇİN GENOM DÜZENLEME İLE 
RAPORTÖR HÜCRE HATLARININ OLUŞTURULMASI 
NAZİFE TOLAY 
Moleküler Biyoloji, Genetik ve Biyomühendislik, Yüksek Lisans Tezi, Temmuz 2018 
Tez danışmanı: Prof. Batu Erman 
Anahtar kelimeler: p53, TALEN, genom düzenleme, hücre temelli reporter 
assay, bileşik tarama 
Dizi özgün transkripsiyon faktörü olarak tanımlanan p53 proteini tumor suppressor olarak 
görev yapar. p53 proteini hücre döngüsünün ve apoptosizin kontrol edilmesinde önemli 
olan çeşitli hücresel süreçlere katılır. p53’ün düzenlenmesi MDM2 ve p53 arasında olan 
otodüzenleyici negatif geri bildirimli döngü tarafından yönetilmektedir. TP53 genindeki 
mutasyonlar ve p53'ün düzenlenmesindeki bozukluklar çoğunlukla tümör başlangıcı, 
invazyon ve metastaz ile ilişkilidir. Bu nedenle p53 fonksiyonlarının restorasyonu kanser 
hücrelerinin canlılığını hedeflemede kullanılmaktadır. Genom düzenleme teknikleri 
mutasyonları düzeltmek, ilgili genleri genoma sokmak ve genleri silmek için etkin bir 
yöntem olarak kullanılmaktadır. p53 proteinin aktivitesindeki değişimleri araştırmak için 
genom düzenleme metodlarını kullanarak raportör hücre hatları geliştirdik. TALEN ile 
uyarılan genom düzenlemenin reportör genin hedeflenen güvenli bölgeye entegre etmek 
için etkin bir yöntem olduğunu gösterdik. Bu raportör hücre hatlarını kullanılarak çeşitli 
bileşiklerin p53'ün transkripsiyonel aktivitesi üzerindeki etkilerini araştırdık ve bazı 
bileşiklerin p53'ün transkripsiyonal aktivitesini arttırdıklarını bulduk. Ayrıca bu 
bileşiklerin p53 varlığında veya p53 yokluğunda hücre canlılığı üzerindeki etkilerini 
analiz ettik ve bileşiklerin p53'ten bağımsız olarak hücre ölümüne neden olduğunu 
gösterdik. Ayrıca, tüm bileşiklerin hücre içindeki p53 proteinini stabilize ettiğini 
belirledik. p53'ün DNA hasarına bağlı translasyon sonrası modifikasyonunun bu 
stabilzayona neden olduğunu gösterdik. Son olarak, bu bileşiklerin MDM2 ve p53 
arasındaki etkileşimi engellemediğini gösterdik. Özet olarak p53 düzenleyen molekülleri 
tanımlamak için tarama araçları geliştirdik ve test ettik. 
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1. INTRODUCTION 
 The p53 Protein 
1.1.1.  The p53 Protein; Cellular Gatekeeper1 
The p53 protein was first identified as a complex with the SV40 large T antigen in 19792. 
In 1983 p53 was cloned from an SV40 virus transformed-mice cell line to demonstrate 
its function and subsequently, it was defined as an oncogene3,4. However; in 1989 an 
observation which showed the inactivation of p53 by retroviral insertion made a striking 
impact on the definition of p53 function. Thereafter, p53 was finally defined as a tumor 
suppressor protein5 and functionalized as a sequence-specific transcription factor6. 
In normal cells, p53 protein cannot be detected because of its short half-life; however, 
activation by several factors such as DNA damage, hypoxia, reactive oxygen species, and 
oncogene activation enables its detection7,8. Upon activation, the p53 protein binds to 
response elements on DNA and regulates the expression of several genes which control 
apoptosis, cell cycle arrest, senescence, and cell metabolism8. The first clearly described 
function of p53 is to induce apoptosis in tumor-derived cell lines9. p53 activates apoptosis 
by using transcription-dependent and -independent mechanism. In the transcription-
dependent activation of apoptosis, p53 induces the expression of proapoptotic genes 
encoding proteins such as BAX, DR5, FAS, PUMA, and NOXA. These proteins can 
either induce the extrinsic apoptotic pathway or the intrinsic apoptotic pathway. 
Translocation of BAX, PUMA, and NOXA to mitochondria induces the loss of 
mitochondrial membrane potential causing the release of Cytochrome c. PUMA can 
initiate a rapid apoptosis response after its expression and is involved in both 
transcription-dependent and -independent apoptosis. In the extrinsic apoptotic pathway, 
p53 activates death receptors on the plasma membrane, such as FAS followed by 
induction of apoptosis10,11. p53 is directly involved in transcription-independent apoptosis 
under certain circumstances:  p53 facilitates BAX-dependent mitochondrial changes by 
going to mitochondria and promotes BAK oligomerization which helps to release 
Cytochrome c10. 
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Another pivotal role of p53 as tumor suppressor protein is the induction of cell cycle 
arrest to regulate cellular growth and to provide additional time for cells to repair DNA 
damage before DNA synthesis12. One of the targets of p53 is p21Waf1/Cip1 which is a cyclin-
dependent kinase (CDK) inhibitor. In the presence of DNA damage, p53 stimulates the 
expression of p21Waf1/Cip1 to induce cell cycle arrest in G1 phase. Overexpression of 
p21Waf1/Cip1 arrests the cell cycle at G1 phase through blocking cyclin E/CDK2-mediated 
phosphorylation of Rb and dissociates of E2F-DP proteins from the Rb complex. Thus, 
this dissociation results in the repression of the expression of required genes for S phase 
entry10. p53 can also induce cell cycle arrest at G2 phase by increasing expression of 
GADD45. GADD45 binds to CDC2 and block cyclin B/CDC2 complex formation 
followed by the inhibition of kinase activity resulting in cell cycle arrest in the G2 
phase1,10. 
In some circumstances, p53 can induce senescence, which is an irreversible cell cycle 
arrest program acting as a barrier against tumorigenesis13. Cellular senescence can be 
initiated in response to telomere dysfunction, oncogene activation, and DNA damage. 
Upon oncogene activation, p53 is upregulated and modulates cellular senescence by 
activating several genes which are involved in senescence. For example, E2F7 is 
upregulated by p53 and functions in the arrest of the cell cycle at mitosis by repressing 
essential mitotic genes, such as CDC2/CDK114,15.  
p53 is also involved in the regulation of autophagy which is defined as self-eating, where 
damaged organelles, misfolded proteins, and other components are degraded by 
specialized lysosomes called autophagosomes. This process allows cells to recycle and 
resynthesize essential structure. As a non-canonical function, p53 can either inhibit or 
activate autophagy depending on its status in cells. For instance, in the presence of stress 
p53 activates autophagosome formation; however, in basal condition p53 has been shown 
to inhibit autophagy16,17.   
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1.1.2. The Structure of p53  
p53 contains an acidic amino-terminal transactivation domain (TAD), which is required 
for the transactivation of target genes, followed by a proline-rich region (PRR). The 
central part of p53 includes a sequence-specific DNA binding domain (DBD), which 
provides specificity for the regulation of target genes. To provide sequence-specific 
binding the DBD needs consensus sequences which contain two copies of the 5‘-
PuPuPuC(A/T)-(T/A)GPyPyPy-3’ motif, separated a by 0-13 base pair spacer10,18. The 
carboxyl-terminal region of p53 contains a tetramerization domain (TD), a nuclear 
localization sequence (NLS) and a nuclear export sequences (NES). The NSL and NES 
are prominent in the shuttling of p53 between nucleus and cytoplasm. Tetramerization of 
p53 ensured by the TD is required for high-affinity DNA binding and for transcriptional 
activation19. The C-terminal region is important for the regulation of p53 and undergoes 
posttranslational modifications such as phosphorylation and acetylation, among 
others20,21,22. These modifications enhance the sequence-specific binding activity of 
p5323. In addition to sequence specificity, the C-terminal region enables stable p53-DNA 
complex formation by inducing conformational changes in the DBD (Figure 1.1)24.  
 
Figure 1.1. The structure of the p53 protein. p53 consist of transactivation domain, a 
proline-rich region, DNA binding domain, tetramerization domain, and regulatory 
domain. 
1.1.3. The Regulation of the p53 Protein 
p53 can be regulated through a variety of mechanisms, the most prominent is carried out 
by MDM2 which is an interacting partner of p5325. The Mdm2 gene was first identified 
on double-minute chromosomes of spontaneously transformed mouse 3T3 fibroblasts and 
then described as an oncogene26. Mdm2 gene expression is controlled by p53 binding to 
N terminus C terminusCentral core
Transactivation 
domain
Proline 
rich 
region
DNA binding domain Tetramerization 
domain
Regulatory 
domain
NLS NES
N C
3931
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the P2 promoter region on the Mdm2 gene27. On the other hand, MDM2 regulates the 
activity of p53 at the protein level27. Therefore, p53 and MDM2 create an autoregulatory 
negative feedback loop.  
Structure of the MDM2 protein is essential to understand its role in the regulation of the 
p53 protein through the autoregulatory negative feedback loop. The 491 amino acid 
MDM2 protein consists of an amino-terminal domain, central acidic domain, and a 
carboxy-terminal RING finger domain28. It also includes a nuclear export sequence, a 
nuclear localization sequence, and a nucleolar localization sequence28. The 
autoregulatory feedback loop between MDM2 and p53 controls the stability and activity 
of the p53 protein in cells29,30,31. In normal cells, the p53 protein is degraded through a 
ubiquitin-dependent mechanism by nuclear and cytoplasmic 26S proteasomes32. The 
ubiquitination of the p53 protein is achieved by MDM2 which has an E3 ubiquitin ligase 
activity28,33. Furthermore, MDM2 can inhibit the transcriptional activity of p53 by 
interacting with the TAD of the p53 protein through its N-terminal region25. MDM2 can 
also promote the nuclear export of p53 by monoubiquitination33. The action of MDM2 
on p53 depends on its protein level: the low levels of MDM2 promotes mono-
ubiquitination and nuclear export of p53, whereas the high levels of MDM2 induces its 
polyubiquitination and nuclear degradation (Figure 1.2)7,34. This regulation mechanism 
keeps the p53 protein at low level in normal cells. In the case of genotoxic stress, p53 and 
MDM2 undergo posttranslational modifications through ATM, ATR, Chk1, and Chk2 
signaling.  Subsequently, the MDM2-p53 interaction is blocked and p53 translocates the 
nucleus to activate its target genes33,35.  
MDMX (also known as MDM4) is another important protein which is involved in the 
regulation of p53. MDMX was first identified to be an interacting partner of p53. Later, 
it was found that MDMX is structurally related with MDM236,37. They have a similar 
acidic core domain and RING domain, although MDMX does not have any E3 ligase 
activity38. MDMX interacts with the transactivation domain of p53 and blocks its 
transcriptional activity. Additionally, MDMX promotes the E3 ligase activity of MDM2 
and prevents MDM2 from autoubiquitination by interacting with the RING domain of 
MDM2 (Figure 1.2)39. As a consequence, MDMX can increase the stability of MDM2. 
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Additionally, p53 can be indirectly regulated by ARF, which is a tumor suppressor 
protein. ARF is induced via oncogenic activation such as Ras and c-myc. The presence of 
oncogene activity results in the elevation of AFR levels, then ARF binds to the RING 
domain of MDM2 to inhibit its E3 ligase activity. In the nucleus, ARF can also sequester 
MDM2 into the nucleolus and then block the MDM2-p53 interaction. Thereby, ARF can 
increase the stability of p53 (Figure 1.2)33,40.   
 
Figure 1.2. The regulation of p53. There is an autoregulatory negative feedback loop 
between p53 and MDM2. p53 stimulates the expression of MDM2; MDM2, in order, 
inhibits the activity of p53 by stimulating its ubiquitin-dependent degradation by the 26S 
proteasome in the cytoplasm or in the nucleus. MDMX can inhibit the activity of p53 by 
binding to its TAD and it also promotes the stability of MDM2. In the presence of DNA 
damage or deregulated oncogenes, p53 is activated by inhibiting the interaction between 
MDM2/X and p53. 
Post-translational modification of the p53 protein is a prominent mechanism to generate 
transcriptionally active p53. The presence of stress is critical to launch an early p53 
response to keep the balance in cells. Post-translational modifications have a crucial role 
to produce p53-dependent early responses35,41. One of the most important post-
translational modifications for the stabilization and activation of p53 is phosphorylation. 
In response to genotoxic stress, p53 is phosphorylated at several residues35.  
Phosphorylation of p53 is mostly associated with its stabilization. However, certain 
phosphorylation in specific residues can increase the transcriptional activity of p53, such 
as Serine33, Theroine55, and Serine31542.  
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Acetylation is another important post-translational modification which occurs at lysine 
residues and can change protein conformation and/or interaction with its partners. This 
modification was first identified on histone proteins and was shown to cause chromatin 
condensation which is a sign for the activation of gene expression. Therefore, acetylation 
is mostly associated with transcriptional activation43. Later, it was shown that non-histone 
proteins are also subjected to this modification. The p53 protein is the first protein that 
was shown to undergo acetylation44. Acetylation of the p53 protein is induced by cellular 
stress and genotoxic insults. The carboxy-terminal domain of p53 is acetylated at several 
specific lysine residues (Lys370, Lys371, Lys372, Lys381, and Lys382) by CBP/p300 
which has histone acetyltransferase activity41,42. Thus, the acetylation of p53 at these 
specific residues results in its stabilization and an increase in its sequence-specific DNA 
binding ability42. In addition to activating p53, acetylation provides efficient recruitment 
of cofactors to stimulate p53 target genes in vivo35. A study showed that the acetylation 
of certain lysine residues is required for p53 to activate certain target genes. For instance, 
Tip60-dependent Lys120 acetylation is necessary for the expression of proapoptotic 
target genes, such as PUMA and BAX, whereas the expression of p21Waf1/Cip1 and Mdm2 
are not changed45,46. Different acetylation patterns of p53 might be related with the 
determination of cell fate depending on the stimulus. Therefore, a variety of post-
translational modifications might produce a barcode that can define the function of p53 
in certain circumstances.   
1.1.4. The Interaction Between p53 and MDM2  
Understanding the interaction between p53 and MDM2 is important to demonstrate the 
regulation mechanism of p53 and is also crucial to clarify p53-dependent cancer 
development. The regions which are involved in the interaction between p53 and MDM2 
protein were revealed by yeast two-hybrid screening and by immunoprecipitation 
experiments47. The N-terminus of the transactivation domain of p53 between 1-41 
residues and the N-terminus of MDM2 between 1-118 residues were determined to be 
essential parts for this interaction47,48. The atomic properties of the interaction were 
determined by X-ray crystallography in 1996 and the residues between 18-26 of p53 were 
mapped as essential residues for the interaction47,49. The high-resolution crystal structure 
of human and Xenopus laevis MDM2 complexed with short p53 peptides indicated that 
MDM2 has a well-defined hydrophobic cleft, which provides a convenient structure for 
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the interaction. This study also showed that three key hydrophobic residues in p53 (Phe 
19, Trp 23, Leu 26), which construct an amphipathic alpha-helix structure, were buried 
into this MDM2 cleft (Figure 1.3)47,50. The interaction is mostly provided by Van der 
Waals contacts that occurred in the hydrophobic cleft. Additionally, two hydrogen bonds 
augment this interaction: one is between Phe19 and Gln72 of MDM2, and another is 
between Trp23 and Leu54 of MDM249. Later, site-directed mutagenesis demonstrated the 
importance of these three key residues for the interaction. Similarly, it was shown that the 
mutations at Gly58, Glu68, Val75, and Cys77 residues in MDM2 protein cause the loss 
of binding ability of MDM2 to p5333.  
 
Figure 1.3. The crystal structure of MDM2-p53 complex. MDM2 possesses a 
hydrophobic cleft, which is occupied by p53 peptide (cyan). p53 can build two hydrogen 
bonds (shown as a red line) with MDM2: Phe19 residue of p53 makes a hydrogen bond 
with Gln72 residue and Trp23 residue of p53 makes a hydrogen bond with Leu54 (PDB 
ID: 1YCR).   
1.1.5.  Mutations in the TP53 Tumor Suppressor Gene 
 Mutations in the TP53 gene can induce development of various cancers due to its diverse 
function in the regulation of cell cycle and apoptosis. Mutations in the TP53 gene can 
lead to deregulated cell cycle, failure in apoptosis and stress signaling. These mutations 
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thus increase genomic instability which is prominent cancer-driving factor51,52. Mutant 
p53-deriving tumor developments have apparently been observed in Li-Fraumeni 
syndrome patients since these patients have germline mutation on TP53 gene. p53 
knockout mouse models also affirmed that the loss of p53 function is often related to 
tumor initiation and progression53,54,55. 50% of human cancers harbor various mutations 
on TP53 gene56. Although p53 mutations can be found almost everywhere in the protein, 
cancer-derived mutations are mostly localized in the DNA binding domain of p53.  Six 
amino acid residues (R175, G245, R248, R249, R273, and R282) located at the DBD of 
the p53 protein have been identified as hotspots for cancer development. Mutations at 
these hotspots affect the binding ability of p53 to target sequences, therefore impair the 
transcriptional activity of p5355,57. Besides, some of the p53 mutations are defined as 
conformational mutations which disrupt the tertiary structure of p53. Hence, the 
conformational mutations might affect the interaction of p53 with other proteins58. 
Additionally, mutant p53 proteins can display a dominant negative effect on the wild-
type p53 by tetramerizing with wild-type p53 and might inhibit the function of wild-type 
p53. Because of the mutations, p53 can also gain new functions which might be 
oncogenic52,56. For instance, a specific mutation that can affect the DNA binding domain 
of p53 without suppressing its transcriptional activation might allow mutant p53 to 
recognize unique response elements to which wild-type p53 does not bind. Hence, mutant 
p53 might show oncogenic function55.  Additionally, it was shown that some of the mutant 
p53 protein promoted cell proliferation, survival, migration, and invasion in tumors56.  
p53 can also lose its activity without having any mutations due to defects in other 
regulator proteins. For example, MDM2 has been found at overexpressed state in some 
cancer cases that prominently keep p53 at the inactive state. Consequently, the 
overexpression of MDM2 provides to cancer cells a growth advantage and promotes 
tumorigenesis58,59. Additionally, the overexpression of MDMX has been detected in some 
tumor cell lines which carry wild-type p53. The knockdown of overexpressed MDMX 
rescued the function of wild-type p53 in breast carcinoma and retinoblastoma cell 
lines58,60.   
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1.1.6. Reactivation of p53 for Cancer Therapy 
The regulation of p53 is pivotal for cells to maintain their healthy state. The mutations on 
the TP53 gene have crucial effects on cancer development. While almost 50% of cancers 
carries mutated TP53 gene, the rest contains wild-type p53 whose regulation is disrupted 
by MDM2/X overexpression or amplification and the loss of ARF60,61. Restoration of 
wild-type p53 functions leads to regression of in situ tumors62. This study has offered a 
possibility to stimulate tumor suppressor activity of p53. Therefore, several different 
therapeutic strategies have been suggested to reactivate wild-type p53 function for cancer 
treatment63.  
Due to fact that the regulation of p53 mostly depends on MDM2, targeting the MDM2 
can be an effective strategy for restoration of p53 functions. A strategy suggested to 
reactivate p53 is to inhibit the E3 ligase activity of MDM2, thus the stability of p53 can 
be increased by preventing its ubiquitination. For this purpose, a compound (HLI98) was 
developed and was shown that it could activate p53. However, its effect on inhibition of 
E3 ligase activity was very low due to its low solubility. This study might be seen as a 
starting point for the development of potent inhibitory compounds64. 
Another promising strategy is that blocking the interaction between MDM2 and p53 by 
small molecules or peptides63. The development of small molecules for inhibiting non-
enzymatic protein-protein interactions is traditionally seen as problemmatic65. However, 
the X-ray co-crystal structure of p53 and MDM2 enables the design of a small molecule 
inhibitor to block the interaction. Because, the hydrophobic pocket of MDM2, which is 
occupied by p53, provides highly suitable structure for the development of small 
molecule inhibitors49,65. Therefore, various studies have been performed to develop small 
molecule inhibitors, and some of these studies have successfully developed small-
molecule inhibitors binding specifically to MDM210.  
In 2004 first potential inhibitor Nutlin, that belongs to the class of cis-imidazoline 
compounds, was discovered by screening synthetic chemical library via surface plasmon 
resonance method. After the discovery of Nutlin, Nutlin-3a which is an enantiomer of 
Nutlin has been developed with higher activity. Nutlin can mimic the interaction between 
MDM2 and p53 properly. A crystal structure of the MDM2-Nutlin-2 complex shows that 
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one bromophenyl moiety perfectly fills the Trp pocket, the other bromophenyl group 
holds the Leu pocket, and an ethyl ether side chain occupies the Phe pocket (Figure 1.4)65. 
Thus, the cis-imidazoline scaffold represents the alpha-helical structure of the p53 peptide 
with high specificity.  
a)                                                                  b)                                                       
  
Figure 1.4. Docking of MDM2-Nutlin-3a. (a) Docking was performed by using 
AutoDock, coordinates of MDM2 and Nutlin-3a were obtained through VMD, and the 
result was analyzed by using Chimera. Nutlin-3a perfectly occupies the hydrophobic cleft 
on the MDM2 protein. (b) Nutlin-3a can perfectly represent Phe, Thr, and Leu residues 
which are important for MDM2-p53 interaction. MDM2 protein structure and Nutlin-3a 
was obtained from PDB (MDM2 PDB ID: 1YCR Nutlin-3a PDB ID: 5C5A). 
In 2005, following the development of Nutlin, benzodiazepinedione-based compounds 
were developed by designing compound libraries by Direct Diversity software and these 
compounds were analyzed by affinity-based screening assay and fluorescent peptide 
displacement assays. The activity of benzodiazepinedione was validated by in vitro 
analysis of p53 target genes66. In 2006, spirooxindoles were reported as new small 
molecule inhibitors. They were developed via structure-based de novo design and their 
binding ability to MDM2 was confirmed by fluorescence polarization-based binding 
assay. After production of the highly active spirooxindole-based compound, its MDM2 
binding mode was analyzed. The spirooxindole-based compound can mimic Phe19, 
Trp23, Leu26 as well as Leu22, which might provide better affinity towards MDM2 than 
Nutlin67. Spirooxindole-based compound MI-219 was shown to selectively kill tumor 
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cells and to increase the expression of p21Waf1/Cip1 and MDM2. MI-219 specifically 
induced apoptosis in wild-type p53 carrying cells rather than mutant p53 carrying cells8.   
An alternative strategy to reactive p53 might be the development of small molecules that 
can bind to p53 and prevent its interaction with MDM2. A compound which is called 
reactivation of p53 and induction of tumor cell apoptosis (RITA) was developed using a 
cell-based assay. RITA stimulated the expression of p53 target genes by blocking the 
interaction between p53 and MDM268.  
The inhibition of the interaction between p53 and MDMX might be another approach to 
increase the efficiency of cancer treatment besides inhibiting p53-MDM2 interaction. For 
this purpose, a few molecules were developed. For example, SJ-172550 was first 
identified compound through biochemical and cell-based assay, which can inhibit 
MDMX. It was indicated that this compound can effectively kill the MDMX 
overexpressing retinoblastoma cells by binding reversibly to MDMX69.  
Moreover, there is another approach that can be applied when tumor cells have mutant 
p53 protein. In the case of tumor cells carrying mutant p53, the main strategy is to refold 
mutant p53 into wild-type conformation to restore its function58.  To reactivate wild-type 
function of the mutant p53 protein, several small molecules were developed. One of them 
is carbazole derivative PhiKan083 which can bind to mutant p53 and then reactivate its 
function by raising its melting temperature. Another small molecule is CP-31398 that 
changed protein folding of the mutant p53 protein into wild-type form that gained its 
original function70. 
 Cell-Based Reporter Assays 
Cell-based assays are effective tools to study signal transduction, gene expression, cell 
proliferation, protein-protein interaction, signal transduction, toxicity and to evaluate the 
activity of novel compounds71. Most widely used application of cell-based reporter assays 
is the investigation of the function of cis-acting elements, such as promoters and 
enhancers (Figure 1.5)72. For instance, after creating mutations on promoter sequences, 
the effects of the mutations can be monitored through reporter genes72. Many cell-based 
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assays are utilized from reporter genes whose products facilitate the development of cell-
based reporter assays. In addition to studying cellular processes, cell-based assays are 
extensively employed for high throughput screening, due to the sensitivity, low labor cost, 
and miniaturization73. On the other hand, cell-based reporter assays have some 
drawbacks. For example, they might need long response time depending on the signal 
cascade or gene expression pathway and they might interfere with other cellular 
pathways71.  Thus, discoveries made with cellular reporter assays must be complemented 
with other in vivo or in vitro tests. 
 
Figure 1.5. Schematic representation of cell-based reporter systems. Cell-based 
reporter system can be created by stable transfection or transient transfection of a reporter 
gene. The external stimulus is translated to the cell by receptors, protein-protein 
interaction, and transcription factors. Translated signal causes a change in reporter gene 
expression which is easily detected. 
There are several considerations to create a cell-based reporter assay. First, cell type 
should be selected carefully. There are two cell type options for the construction of cell-
based assays which are immortalized cell lines and primary cell lines71. Secondly, cell-
based reporter assays need a highly detectable expression of the reporter gene which can 
be provided either transient or stable transfection. Because of the variation of transient 
transfection efficiency, stable transfection is the more reliable way to create reporter cell 
lines. Stable expression can provide long-term, consistent expression for reporter genes. 
Finally, when a reporter system is designed, properties of the promoter and upstream 
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control elements of the reporter gene should also be considered. Because constitutive 
cryptic promoter activity can affect the sensitivity of assays, potentially a transcription 
stop element should be inserted upstream of the promoter of choice. The half-life of the 
reporter protein is also important to design a reliable assay, because a long half-life might 
increase background, decrease response sensitivity and cause false-positive results74.  
There are several reporter genes that have been used for the construction of cell-based 
reporter assays for over a decade. Reporter genes can be grouped as intracellular and 
extracellular. While intracellular reporter gene products retained in the cell, extracellular 
gene products are transported into the cell culture medium73. Chloramphenicol acetyl 
transferase (CAT), which is a bacterial enzyme, has been utilized to study transcriptional 
regulation in mammalian cells. CAT is basically trimeric protein which is composed of 
three identical subunits of 25 kDa and catalyzes the switch of an acetyl group from acetyl-
coenzyme A to chloramphenicol. It is a very good candidate as a reporter gene and widely 
used to study the regulation of gene expression in mammalian cells because there is no 
counterpart of this enzyme in mammalian cells. Thus, it does not cause any conflict 
between endogenous and ectopic expression. However, this method requires the use of 
C14 radioisotope-labeled acetyl CoA, which limits its use in living cells75. Beta-
galactosidase (β-gal) is also bacterial enzyme which is encoded by the lacZ gene. Its 
activity in cells can be detected easily with a colorimetric assay. This enzyme can 
hydrolyze various β-galactoside molecules. For example, 5-bromo-4-chloro-3-indolyl 
galactoside (X-Gal) is cleaved and indolyl group is released from the substrate. This 
hydrolysis enables the easy detection of the reporter protein, because free indolyl 
produces an indigo blue insoluble derivative by oxidation. Therefore, β-galactosidase is 
extensively used as an internal control for normalization of variability in reporter protein 
activity, due to differences in transfection efficiency75,76. Beta-lactamases are crucially 
important for bacteria to gain resistance against penicillin and cephalosporin-based 
antibiotics. The genes that encode these enzymes have also been used as reporter genes 
for studying gene expression in vitro and in vivo. For instance, TEM-1 β-lactamase has 
been used to detect protein-protein interactions and other biological processes75. Alkaline 
phosphatase is yet another reporter gene and its secreted form is widely used to observe 
inflammatory events, for high throughput compound screening, and to study promoter 
activity. The secreted alkaline phosphatase enables easy detection from cell culture 
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medium without the need to lyse the producing cells 75,76. Green fluorescent protein (GFP) 
is a very convenient reporter gene which does not have any enzymatic activity in contrast 
to other reporter genes. GFP has originated from jellyfish Aequorea victoria. GFP is 
particularly used to visualize protein localization, spatial gene expression, and protein-
protein interaction. Despite its wide usage, it cannot be counted as quantitative reporter 
gene77. Luciferase enzymes are widely used as reporters, thanks to the bioluminescence 
features of their products, which can cover wide dynamic range of gene activity. 
Luciferases which generate very bright bioluminescence have been utilized to create cell-
based reporter assays78. Luciferase genes which are originated from firefly Photinus 
pyralis, jellyfish Aequorea Victoria, and sea pansy Renilla reniformis are mostly used to 
construct bioluminescence reporter assay. In the presence of oxygen, magnesium ion, and 
ATP, firefly luciferase catalyzes the oxidation of luciferin and produces light with broad-
band emission spectra and this light can be detected easily by luminometers71,75. Due to 
its sensitivity and easy detection, firefly luciferase has been employed for the examination 
of the activity of transcription factors and screening of inhibitor or activator molecules79. 
Additionally, luciferases are excellent reporter genes to study cellular processes and to 
establish high throughput screening methods, because they do not require post-
translational modifications and also they do not have any counterpart in mammalian 
cells75.  
 Genome Editing 
Genome editing is a current and effective method broadly applied in biomedical research, 
medicine and biotechnology. It is a powerful tool to study the regulation of gene 
expression, to investigate the function of the genes, and to change genome architectures. 
In detail, genome editing can be used to knock out specific genes by non-homologous end 
joining (NHEJ) which causes insertions and deletions resulted in frameshifts in the coding 
region followed by gene disruption80.  Most attractive use of genome editing is its ability 
to insert a gene of interest into targeted site by homology directed repair (HDR). 
Engineered nucleases can increase the specificity of homology-directed repair by creating 
site-specific double strand breaks81. Particularly, gene insertion through genome editing 
requires a specific donor DNA which should contain the 
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homology arms that are homologous to the targeted site80.  In addition to gene insertion 
and deletion, genome editing tools can be used to correct or to introduce the point 
mutations in the genome through the delivery of engineered nucleases with specific 
vectors82 or with single-strand oligodeoxynucleotides83.  
1.3.1. Programmable Nucleases   
Historically, the genome editing approach has utilized programmable nucleases, which 
can be classified as zinc-finger nucleases (ZFNs), transcription activator-like effector 
nucleases (TALENs), and clustered regularly interspaced short palindromic repeats 
(CRISPR) and CRISPR-associated system 9 (Cas9) enzyme84. ZFNs have been used to 
modify the genome in vitro or in vivo. ZFNs consist of the DNA restriction domain of the 
Fok I restriction endonuclease fused to a Cys2-His2 zinc-finger DNA binding domain 
which can be designed to bind target sequences85. The Cys-2-His2 zinc-finger domain is 
the most common DNA-binding motif found in eukaryotic transcription factors86. Every 
zinc-finger motif contains approximately 30 amino acids in a conserved ββα 
configuration and the α-helix usually makes a contact with three base pairs located in the 
major groove of DNA with different selectivity86,87. ZFNs have been designed to work as 
a dimer: each monomer of the ZFN binds to a half of the target site through its DNA 
binding domain which guides the dimerization of  the Fok I domain, which creates 
specific double strand breaks85. ZFNs have two main disadvantages which are the 
difficulties of assembling multiple zinc finger motifs that generate a sequence-specific 
DNA binding domain and the off-target issue. Nevertheless, ZFNs have a prominent 
potential for efficient genome editing84. 
Another nuclease generated from genome engineering, TALENs also use the Fok I 
cleavage domain88. To recognize DNA specifically, these human-made nucleases use 
transcription activator like-effector (TALE) domains copied from natural bacterial 
effector TALE from bacterial  Xanthomonas sp. to regulate gene transcription in host 
plants for providing an advantage for bacterial colonization89. Natural TALE proteins 
contain a central DNA binding domain, a type II secretion signal, a nuclear localization 
signal, and a transactivation domain. The DNA binding domain is composed of 
monomers, which are tandem repeats of conserved 34 amino acid residues. In these 
repeats, only two amino acid residues located at positions 12 and 13 are highly variable 
and they provide specificity for the recognition of DNA and are called repeat variable di-
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residues (RVD)86. In contrast to zinc-fingers, where one finger contacts 3 nucleotides, 
each TALE motif can only recognize a single nucleotide which is determined by the 
identity of the RVD.  
A natural code determining the recognition specificity was recently discovered, where the 
identity of the amino acid residues of the RVD is used recognize the four DNA bases: 
TALE repeats that contain RVD amino acids NI recognize A, HD recognize C, NG or 
HG recognize T, NN recognize G or A. Unlike zinc-fingers, each TALE motif provides 
mostly individual recognition as independent from neighboring motifs90. Because TALEs 
bind to DNA with high specificity, they have been used for genome editing90. For that 
purpose, multiple repeats forming the DNA binding domain of the TALE were fused to 
Fok I nuclease coding sequences in a plasmid. The protein product is referred as 
transcription activator like-effector nuclease (TALEN)88. To function properly, TALENs 
require two pairs which bind to the target sequence in a head to head opposite orientation 
and thus leaving a spacer sequence between the DNA recognition sequences.  Once a 
TALE pairs binds to the target sequence, the Fok I domains homodimerize and induce a 
double-strand break in the spacer sequence91. Additionally, target site selection is 
important to design efficient TALENs. For target site selection, there is a structural 
limitation which requires the presence of a T before the 5’ end of the target sequence91. 
Unfortunately, TALENs have some drawbacks, especially in their construction. The 
construction of TALENs is cumbersome because of the large number of repeated motifs. 
To deal with this issue, several methods have been developed, such as Golden Gate 
cloning92 and ligation-independent cloning93. As a result, the enhanced efficiency and 
simpler construction protocols compared to ZFNs, make TALENs an attractive tool for 
genome editing90.  
The latest version of programmable nuclease is the CRISPR/Cas9 system. CRISPR/Cas9 
system was discovered in bacteria which uses this system as an adaptive defense 
mechanism90. CRISPR/Cas9 system is composed of a guide RNA and the Cas9 enzyme. 
While guide RNA directs sequence-specific recognition, Cas9 enzyme mediates DNA 
cleavage91. Cas9-mediated cleavage of DNA is linked to guide RNA (gRNA) which is 
customizable and provides sequence specificity for DNA cleavage90.  To cleave DNA, 
Cas9 enzyme also requires a specific three base pairs-sequence which must contain 5’-
NGG-3’ or 5’-NAG-3’ before the gRNA binding site in the target sequence. These 
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sequences are called the protospacer adjacent motif (PAM)80. CRISPR/Cas9 system has 
simpler construction procedure compared to other programmable nucleases and it also 
has better or equal efficiency80,81. For this reason, it has been the most popular choice in 
genome editing systems. Because of pre-existing reagents, we chose the TALEN method 
to target the human genome in this thesis. However, the CRISPR/Cas9 enzymes targeting 
the same site in the human genome have also been developed. 
Overall, these programmable nucleases recognize specific sites and generate a double 
strand break on the DNA. This double strand break can be repaired by the cells with two 
different mechanisms: non-homologous end-joining (NHEJ) and homology-directed 
repair (HDR) (Figure 1.6)94,95.  
 
Figure 1.6. DNA double strand break repair. DSBs are repaired through non-
homologous end joining (NHEJ) or homology-directed repair (HDR).  
In NHEJ repair, Ku70/80 binds to the end of the broken DNA to recruit other proteins 
which form a stable repair complex on DSB.  Then, broken ends are processed by specific 
DNA end-processing enzymes to create compatible ends for ligation. In the final step of 
NHEJ, the broken ends get ligated to each other by DNA Ligase IV96. The NHEJ pathway 
performs an error-prone repair, thus resulting in insertions and deletions (INDELs)95. In 
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HDR, the broken ends are processed by the Mre11/Rad50/Xrs2 complex and Sae2 protein 
to generate free 3’ single-strand ends which produce D-loop by attacking to undamaged 
DNA duplex with the help of Rad51 filaments. This mechanism is called stand invasion. 
After D-loop creation, DNA polymerase synthesizes new DNA by using undamaged 
DNA as template. Subsequently, new synthesized DNA is dissociated form 
heteroduplex97. In contrast to NHEJ, HDR provides accurate repair for cells, however, its 
frequency is lower than NHEJ95. These two repair mechanisms can be used for different 
applications genome editing technology. While NHEJ is used for mutation generation, 
HDR is employed for targeted gene integration and gene correction. The outcome of HDR 
depends on the design of donor DNA carrying the gene of interest flanked with suitable 
homologous sequences94,98. 
1.3.2. Genomic Safe-Harbors (GSHs) 
GSHs are found in the genome located in intragenic or extragenic regions and provide 
reliable and stable transgene expression99,100. GSHs are valuable sites for targeted gene 
integration. In contrast to random integration, the fate of targeted gene insertion is more 
predictable in terms of position effects and silencing100. Determination of genomic sites 
as safe harbors depend on several criteria. For example, its proximity to tumor suppressor 
genes and oncogenes is important to define the risk of malignant transformation. Several 
studies about integration-dependent activation of cancer genes have identified unsafe sites 
for integration99. Additionally, transformation promoting sites and promising safe-harbor 
sites have been investigating by retroviral gene trap screening101. According to these 
criteria, the human genome has three genomic safe harbor sites which have been 
employed for transgene insertion. These are the adeno-associated virus integration site 1 
(AAVS1), a human orthologue of the mouse ROSA26 locus, and the chemokine receptor 
5 (CCR5) gene locus. The murine ROSA26 locus was found by retroviral gene trapping 
screen102. This region has been widely used to insert transgenes into the mouse genome103. 
The CCR5 gene encodes a major co-receptor for HIV-1 and its null mutation provides 
resistance for HIV-1 infection104. However, recently it was observed that CCR5 knock-
out mice display susceptibility to West Nile virus infection100. Although there is a safety 
issue, the CCR5 locus has been used for transgene integration.  
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The intron 1 of the protein protease 1-regulatory subunit 12C (PPP1R12C) gene on 
human chromosome 19 is mostly employed for the gene integration by adeno-associated 
viruses (AAVs).  The intron 1 is referred to as the AAVS1 locus105,106. The AAVS1 locus 
has been utilized for a long term, stable transgene expression. The disruption of 
PPP1R12C by transgene integration has not been reported as being related to any known 
abnormalities81.  
As a conclusion, transgene integration into genomic safe-harbors has many advantages. 
For instance, it provides predictable gene expression and reduces the risk of unwanted 
integration. The gene integration can be achieved by using ZFN, TALEN or 
CRISPR/Cas9 system through a creation of DSB on DNA and by applying homology-
directed repair to integrate the gene of interest into the genome107. This thesis uses this 
approach to generate human cell lines used as reporters of transcription. 
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2. AIM OF THE STUDY 
In the first part of the study, we aimed to generate reporter cell lines by using genome 
editing tools to investigate the activity of p53. For this purpose, we generated a donor 
DNA which includes homology arms targeting the human AAVS-1 genomic safe harbors, 
puromycin gene for selection and a luciferase cassette, which contains thirteen p53 
binding sites (p53 response elements), a heterologous promoter, and the firefly luciferase 
gene. In this reporter system, luciferase expression is activated by the binding of p53 to 
its response elements located upstream of the promoter of the luciferase gene. To integrate 
the luciferase cassette and puromycin gene into the genomic safe-harbor AAVS-1 site, 
HCT 116 WT cell line was cotransfected with customized TALENs and donor DNA.  
Besides, TALEN-dependent genome editing, we conducted another experiment to create 
reporter cell line by using another approach, which is random integration. For random 
integration, we used two different plasmids. One of these includes a luciferase cassette 
for the construction of reporter system and the other plasmid contains the neomycin gene 
for selection. HCT 116 WT cell lines were cotransfected with these two plasmids.   
In the second part of the study, we aimed to screen a variety of small molecule compounds 
to reveal their effects on cell viability, DNA damage, and the accumulation, 
posttranslational modification, and activation of the p53 protein. Principally, p53 can be 
activated by several factors, such as DNA damage, oxidative stress, and small-molecule 
inhibitors that separate it from its inhibitor MDM2. Upon activation, p53  translocate to 
the nucleus to activate the expression of its target genes35. In detail, the aim of the cell 
viability assay was to check the impact of the compounds on cell viability and to study 
whether the compounds cause cell death in a p53-dependent manner. To evaluate the 
impact of the compounds on the accumulation of the p53 protein, we decided to check 
total p53 protein levels by western blotting. To determine if the accumulation of p53 
results from its specific phosphorylation, we selected the serine 15 residue of the p53 
protein whose phosphorylation is induced by DNA damage signaling and performed 
western blotting to determine Ser15 phosphorylation levels.  
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We also aimed to study the effect of the compounds on DNA in terms of the induction of 
double-strand breaks. For this purpose, we determined changes in phospho-H2A.X levels 
which is an indicator of the presence of double-strand breaks by western blotting. Another 
goal was to investigate the effect of compounds on p53 activity. To carry out this goal, 
we generated a cell-based reporter system. By using this system, we identified the changes 
in the transcriptional activity of p53 depending on treatment with a variety of compounds.  
The last goal of the study was to identify whether the chemical compounds being tested 
have any potential to block the interaction between MDM2 and p53 by using the 
fluorescent two-hybrid assay and live cell imaging. 
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3. MATERIALS & METHODS 
 Materials 
3.1.1. Chemicals 
Chemicals used in this thesis are presented in Appendix A. 
3.1.2. Equipment 
Equipment used in this thesis are presented in Appendix B. 
3.1.3. Solutions and Buffers 
Calcium Chloride (CaCl2) Solution: 60 mM CaCl2 solution, 15% Glycerol, 10 mM 
PIPES (pH 7.0) solution were mixed and total volume completed to 500 ml with distilled 
H2O (dd H2O). The solution was filter sterilized and stored at 4°C.  
Agarose Gel: For 100 ml 1% w/v agarose gel, 1 g of agarose powder was dissolved in 
100 ml 0.5X TBE buffer by heating and 0.002% (v/v) ethidium bromide was added to the 
solution.  
Tris-Borate-EDTA (TBE) Buffer: For 1 L 5X stock solution, 54 g Tris-base, 27.5 g boric 
acid, and 20 ml 0.5M EDTA (pH 8.0) were dissolved in ddH2O. The solution is stored at 
room temperature.  
Phosphate-Buffered Saline (PBS): For 1 L 1X solution, 100 ml 10X PBS was mixed with 
900 ml ddH2O to make 1 L solution. The solution was filter-sterilized.  
PBS-Tween20 Solution (PBS-T):  For 1 L 1X solution, 0.5 ml Tween20 was added into 
1L 1X PBS. 
Blocking Buffer: For 10 ml blocking buffer, 0.5 g skim milk powder was dissolved in 10 
ml PBS-T. 
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Protein Loading Buffer: For 10 ml 4X protein loading buffer, 2.4 ml Tris-base (1M pH 
6.8), 0,8 g SDS, 4 ml glycerol (100%), 0.01% bromophenol blue, and 2 ml β-
mercaptoethanol were mixed in ddH2O.  
SDS Separation Gel: For 10 ml 10% gel, 2,5 ml Tris (1.5M pH 8.8), 4 ml ddH2O, 3.34 
ml Acrylamide/Bis-acrylamide (29:1), 100 µl 10%SDS, 100 µl 10% APS, and 10 µl 
TEMED were mixed. 
SDS Stacking Gel: For 5 ml 4% gel, 1.25 ml Tris (0.5M pH 6.8), 2.70 ml ddH2O, 1 ml 
Acrylamide/ Bis-acrylamide (29:1), 50 µl 10%SDS, 15 µl %10 APS, and 7.5 µl TEMED 
were mixed. 
Tris-Glycine Solution: For 1L 10X stock solution, 40 g Tris base, 144 g Glycine were 
dissolved in dH2O and its pH was adjusted to 8.3. For 1X SDS running buffer, 100 ml 
tris-glycine solution was mixed with 895 ml dH2O and 5 ml 20% SDS solution. For 1X 
transfer buffer, 100 ml Tris-glycine solution was mixed with 200 ml methanol, and 700 
ml dH2O.  
Antibody Dilution Solution: 1% BSA, and 0.5% sodium-azide in PBS-T. 
Enhanced Chemiluminescence (ECL) Solution: For 5 ml ECL, 234 ml Tris (1.5M pH 
8.8), 25 µl luminol, 12,5 µl coumaric acid, 4.728 ml ddH2O, and 1.5 µl H2O2 were mixed.  
Polyethyleneimine (PEI) Solution: For 1mg/ml solution, 20 mg polyethyleneimine 
powder was dissolved in 20 ml ddH2O by heating at 80°C and the pH was adjusted to 7.0 
with hydrochloric acid (HCl). The solution was filter-sterilized, aliquoted as 1 ml in each 
1.5 ml tube and kept at -20°C.  
3.1.4. Growth Media 
Luria Broth (LB): To prepare 1 L LB media, 20 g LB powder was dissolved in 1 L ddH2O 
and then autoclaved at 121°C for 15 minutes. For selection, ampicillin at a final 
concentration of 100 µg/ml, kanamycin at final concentration 50 µg/ml was added to the 
liquid medium just before use. 
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LB-Agar:  To prepare 1 L LB-agar medium, 35 g LB-Agar powder were dissolved in 1 L 
ddH2O and then autoclaved at 121°C for 15 minutes. After cooling down to 50°C the LB-
Agar solution was poured into sterile petri dishes. Before pouring onto sterile petri dishes, 
ampicillin at a final concentration of 100 µg/ml or kanamycin at a final concentration of 
50 µg/ml was added to the medium for selection. Sterile agar plates were kept at 4°C. 
DMEM: DMEM is supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
and 1% Pen-Strep (100 U/mL Penicillium and 100 µg/mL Streptomycin).  
Freezing Medium: Heat-inactivated FBS containing 10% DMSO (v/v) was filtered-
sterilized. 
3.1.5. Molecular Biology Kits 
Commercially available molecular biology kits used in this thesis given in Appendix C. 
3.1.6. Enzymes 
Restriction enzymes, DNA modifying enzymes, polymerase enzymes, and their 
corresponding buffers were obtained from either New England Biolabs (NEB) or 
Fermentas.   
3.1.7. Antibodies 
Antibodies used in this thesis are given in Appendix D. 
3.1.8. Bacterial Strains 
E. coli DH-5D strain is used for general transformation and cloning applications. 
3.1.9. Mammalian Cell Lines 
Human colorectal carcinoma cell line, its p53-null derivative (ATCC CCL-24TM) and 
Baby hamster kidney cell line (ChromoTek) are used in this thesis.  
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3.1.10. Plasmids and Primers 
Oligonucleotides which were used in this thesis are shown in Table 3.1. 
OLIGONUCLEOTIDE 
NAME 
SEQUENCE PURPOSE OF 
USE 
AAVS forward CTGTCTCTGACCTGCATTC PCR 
AAVS reverse GGTCCAGGCCAAGTAGGTG PCR 
Luciferase forward ATCTTCCAGCGGATAGAATGGC PCR 
Luciferase reverse GGAGGAGTTGTGTTTGTGGACGAAG PCR 
HA-R reverse CTCAGGTTCTGGGAGAGGGTAG PCR 
Table 3.1. List of oligonucleotides. 
Plasmids which were used in this thesis are shown in Table 3.2. 
PLASMID NAME PURPOSE OF USE SOURCE 
pSV2-Neo Selection plasmid containing 
neomycin gene for selection 
ATCC 
pG13-luc Donor plasmid for luciferase 
cassette 
Addgene (#16442) 
pGL3-Basic Intermediate plasmid for 
construction of luciferase cassette  
Promega 
AAVS1 SA-2A-puro-
pA-donor plasmid 
Plasmid for donor DNA 
construction 
Addgene (#22075) 
hAAVS1 1L TALEN Mammalian expression plasmid 
for TALEN system  
Addgene (#35431) 
hAAVS1 1R TALEN Mammalian expression plasmid 
for TALEN system 
Addgene (#35432) 
pcDNA3-GFP To check transfection efficiency Lab construct 
Table 3.2. List of plasmids. 
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3.1.11. DNA and Protein Molecular Weight Markers 
DNA ladders and protein ladders used in this thesis are given Appendix E. 
3.1.12. Software, Computer-based Programs, and Websites 
Software, computer-based programs, and websites used in this thesis are given in Table 
3.3. 
SOFTWARE, 
PROGRAM, 
WEBSITE NAME 
COMPANY/WEBSITE PURPOSE OF 
USE 
CLC Main 
Workbench v7.9.4 
QIAGEN Bioinformatics Molecular 
cloning 
NCBI PRIMER-
BLAST 
https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
Basic local 
alignment tool, 
primer design 
Ensembl Genome 
Browser 
http://www.ensembl.org  Human genome 
information 
Addgene https://www.addgene.org  Plasmid map 
information 
Chimera https://www.cgl.ucsf.edu/chimera/ 
 
Visualization of 
PDB files 
Visual Molecular 
Dynamic (VMD) 
http://www.ks.uiuc.edu/Research/vmd/ 
 
Analysis PDB 
files 
AutoDock http://autodock.scripps.edu/ 
 
Docking 
IN Cell Developer GE Healthcare Analysis of 
colocalization  
Table 3.3. List of software, computer-based programs and websites. 
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 Methods 
3.2.1. Bacterial Cell Culture 
3.2.1.1. Bacterial culture growth  
E. coli DH5D strain was cultured in LB supplemented with appropriate antibiotic for 
overnight (16 hours) at 37°C with shaking at 221 rpm. In order to obtain single bacterial 
colonies, bacterial culture was spread onto petri dishes containing LB-agar with suitable 
antibiotic by using glass beads and they were incubated overnight (16 hours) at 37°C 
without any shaking. For long term storage, bacterial culture was mixed with the sterile 
glycerol at 10% (v/v) final concentration in a cryo-vial. Bacterial glycerol stocks were 
stored at -80°C. 
3.2.1.2. Preparation of competent bacteria 
Previously prepared competent E. coli DH5D strain was inoculated in 50 ml LB without 
any antibiotic in a 200 ml flask and incubated overnight at 37°C by shaking at 221 rpm. 
Next day, 4 ml from overnight grown bacterial culture were inoculated in 2 L flask 
containing 400 ml LB without antibiotic and incubated at 37°C with shaking at 221 rpm 
until the optical density of the culture reached to 0.375 at 590 nm. 400 ml culture was 
divided into 8 sterile 50 ml polypropylene tubes and incubated on ice for 10 minutes, 
followed by a centrifugation at 1600 rcf for 10 minutes at 4°C. Then supernatant was 
removed, and each bacterial pellet was resuspended in 10 ml ice-cold CaCl2 solution and 
centrifuged at 1100 rcf for 5 minutes at 4°C. Each bacterial pellet was resuspended again 
in 10 ml ice-cold CaCl2 solution and incubated on ice for 30 minutes. Following the final 
centrifugation at 1100 rcf for 5 minutes at 4°C, the pellets were resuspended in 2 ml ice-
cold CaCl2 solution and all bacterial suspensions were pooled in one polypropylene tube. 
The suspension of competent bacteria was dispensed into 200 µl aliquots into pre-chilled 
microcentrifuge tubes. Competent cells were frozen immediately in liquid nitrogen and 
were stored in -80°C freezer.  
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Transformation efficiency of the competent bacteria (typically107-108 cfu/Pg) was 
calculated by transforming of pUC19 plasmid at different concentrations (1000-100-10 
pg) by using heat-shock transformation method.  
3.2.1.3. Transformation of competent bacteria 
Heat-shock transformation method was applied through all transformation experiments. 
Chemically competent E. coli DH5D cells were taken from -80 C and thawed on ice. 
While 1 pg-1 ng DNA was mixed with competent bacteria for pure plasmid 
transformation, 5 µl- 20 µl ligation mix was added into competent bacteria for ligated 
product transformation. The cells were then incubated on ice for 30 minutes. After the 
incubation period, the cells were heat-shocked at 42°C for 90 seconds and placed again 
on ice for 2 minutes. 800 µl LB (without any antibiotic) was added on the heat-shocked 
cells and this culture was incubated at 37°C for 45 minutes. After the incubation cells 
were spread with glass beads on LB-agar plate containing appropriate antibiotic for 
selection. The plates were incubated at 37°C overnight (16 hours) without any shaking.    
3.2.1.4. Plasmid DNA isolation  
Plasmid DNA isolation from bacteria was performed by using alkaline lysis protocol as 
described in Molecular Cloning: A Laboratory Manual (Sambrook et al). In addition to 
alkaline lysis protocol, PureLink HiPure Plasmid Midiprep and ZymoPure Plasmid 
Maxiprep commercial kits were employed for plasmid DNA isolation according to 
manufacturer protocols.  
3.2.2. Mammalian Cell Culture 
3.2.2.1. Maintenance of cell lines  
HCT 116 WT cells, HCT 116 p53-/- cells, and BHK cells were maintained in DMEM 
medium in sterile tissue culture plates and incubated in an incubator set to 37°C with 5% 
CO2. When the confluency of the cells reached to 80%, the cells were split into sterile 
tissue culture plate containing pre-warmed, fresh medium with a 1:10 ratio.  
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3.2.2.2. Cell cryopreservation  
Cells were frozen in the freezing medium for later use and storing at early passage. The 
cells at the exponential growth phase were counted and centrifuged at 300 rcf for 5 
minutes. 1-5x106 cells were resuspended in 1 ml freezing medium and transferred into 
cryovials. Cryovials were placed into a freezing container and stored at -80°C freezer for 
at least 24 hours and then transferred to liquid nitrogen tank for long term storage.  
3.2.2.3. Thawing frozen mammalian cells  
Cryovial was removed from liquid nitrogen storage and thawed. After thawing the cells, 
they were immediately mixed with 9 ml growth medium in 15 ml centrifuge tube to dilute 
DMSO in the freezing medium. The cells were centrifuged at 300 rcf for 5 minutes to 
remove any residual DMSO. Cell pellet was resuspended in DMEM medium. The cells 
were placed into sterile tissue culture plate and incubated at 37°C with 5% CO2. 
3.2.2.4. Transient transfection of mammalian cells by polyethyleneimine (PEI) 
One day before the transfection, the required number of cells were split onto 6-well tissue 
culture plate. On the day of the transfection, 3 µg of total plasmid DNA was mixed in 200 
µl serum-free phenol-free DMEM in a sterile microcentrifuge tube. PEI (1µg/µl) was 
added to the DNA-DMEM mix at a 3:1 ratio of PEI (µg) to total plasmid DNA (µg) and 
mixed immediately by vortex. After 15 minutes of incubation at room temperature, the 
mixture was added dropwise onto the cells.     
3.2.2.5. Genomic DNA isolation        
Genomic DNA isolation was performed by PureLink Genomic DNA Mini Kit and 
Multisource Genomic DNA Miniprep Kit according to manufacturer’s protocol.  
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3.2.3. Vector Construction 
3.2.3.1.  Vector construction protocol 
Restriction enzyme digestion: Digestion reactions were performed by mixing desired 
amount of DNA and required enzymes with their compatible buffers in PCR tube, 
followed by incubation in Thermal Cycler for 1-3 hours at the optimum temperature 
regarding to the enzyme.  
De-phosphorylation of 5’ phosphate groups: If the plasmid DNA was digested with a 
single enzyme or compatible enzymes and was planned to be used in a ligation reaction, 
then 5’ phosphate groups of linearized plasmids were removed by alkaline phosphatase 
enzyme (calf intestinal alkaline phosphatase, (CIAP) to block self-ligation.  
Agarose gel electrophoresis and DNA purification from the gel:  PCR products, digestion 
reaction and other DNA samples were separated and visualized by agarose gel. Gel were 
prepared by dissolving the required amount of agarose depending on the size of the DNA 
fragment (in 0.7-2 g range) in 100 ml 0.5X TBE. This mixture was heated in a microwave 
in order to completely dissolve the agarose. The solution was then cooled down and 2 µl 
ethidium bromide (0.002% v/v) was added. DNA samples were mixed with DNA loading 
dye and loaded into solidified agarose gel and electrophoresis was performed at 100V for 
45-90 minutes in 0.5X TBE. For the gel extraction DNA band of interest was cut from 
the gel under the UV light with minimum UV exposure. DNA was purified by 
commercially available gel purification kits. For the visualization of the bands Bio-Rad 
Image Analyzer was used. 
Ligation: Ligation reactions were performed by utilizing T4 DNA Ligase (NEB) with 
appropriate buffer. For all ligation experiments, 1:3 vector versus insert ratio was 
considered. Ligation was performed either at 16°C for 16 hours or at room temperature 
for 4 hours. In each cloning, vector only ligation was performed to control if self-
assembly is occurred. The ligation reaction was transformed into chemically competent 
E. coli DH5α bacteria and plated onto LB-agar petri dishes containing appropriate 
antibiotic for selection and incubated at 37°C for 16 hours without any shaking.  
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3.2.3.2. Donor DNA construction 
Intermediate vector construction: To construct a cassette which includes p53 binding 
sites, a promoter, and a luciferase gene, pGL-3 basic vector was used as backbone, since 
it has own luciferase gene. p53 binding sequences and promoter sequences were obtained 
from pG13-luc (wild-type p53 binding sites) plasmid by restriction digestion. The 
digestion reaction was incubated at 37°C for 2 hours to obtain linearized-vector and insert. 
After digestion reaction 1,5 µl CIAP (20,000U/ml-Fermentas) was directly added into 
reaction mix and incubated at 37°C for 30 minutes. Digested products were run on 1% 
agarose gel and linearized-vector and insert were extracted from the gel. 
 pGL3-Basic (vector) pG13-luc (insert) 
Plasmid DNA 1 µg 3 µg 
Cutsmart-Buffer (NEB) 5 µl 5 µl 
Hind III-HF (20,000U/ml) 
(NEB) (NEB) 
2 µl 2 µl 
ddH2O To 50 µl To 50 µl 
Before ligation reaction, control gel was performed to calculate required amount of vector 
and insert for ligation. Afterward, ligation reaction was performed as considered to 3:1 
insert to vector molar ratio. The ligation reaction was performed either at 25 °C for 4 
hours or 16 °C for overnight. Following the incubation, transformation was performed. 
 1.condition 2.condition Control 
Vector  3 µl 6 µl 3 µl 
Insert  1 µl 2 µl - 
T4 ligase (4000,000 U/ml) 
(NEB) 
1 µl 1 µl 1 µl 
T4 ligase buffer (NEB) 2 µl 2 µl 2 µl 
ddH2O To 20 µl To 20 µl To 20 µl 
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Diagnostic digestion reaction was performed with Xho I and Eco RI-HF enzymes to select 
the correct intermediate vector.  
Plasmid DNA 1 µg 
Cutsmart Buffer (NEB) 2 µl 
Xho I (20,000U/ml) (NEB) 0,3 µl 
Eco RI-HF (20,000U/ml) (NEB) 0,3 µl 
ddH2O To 20 µl 
The digestion reaction was incubated at 37°C for 2 hours and digestion reaction was run 
on 2% agarose gel to select positive colony having insert. 
Donor vector construction: To obtain final construct, which has right and left homology 
arms, a puromycin gene, and luciferase cassette (p53 binding sites, promoter and 
luciferase gene), second cloning experiment was performed. The AAVS1 SA-2A-puro-
pA donor plasmid was used to create final donor vector. The luciferase cassette was 
obtained from the intermediate vector. While the AAVS1 SA-2A-puro-pA donor plasmid 
cut with Sal I, insert was obtained from intermediate vector by cutting with Sal I and Xho 
I. Due to compatibility between Sal I and Xho I, vector and insert ligated each other 
successfully.   
 AAVS1 SA-2A-puro-pA 
donor (vector) 
Intermediate vector (insert) 
DNA 1 µg 1 µg 
NEB 3.1 Buffer 5 µl 5 µl 
Sal I (20,000U/ml) (NEB) 1 µl 1 µl 
Xho I (20,000U/ml) (NEB) - 1 µl 
ddH2O To 50 µl To 50 µl 
Before the ligation reaction, control gel was performed to calculate required amount of 
vector and insert for ligation. Then, ligation reaction was performed as considered to 4:1 
insert to vector molar ratio. The ligation reaction was performed either at 25 °C for 4 
hours or 16 °C for overnight. Following the incubation, transformation was done. 
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 1.condition 2.condition Control 
Vector  2 µl 3 µl 2 µl 
Insert  4,4 µl 6,6 µl - 
T4 ligase (4000,000 U/ml) (NEB) 1 µl 1 µl 1 µl 
T4 ligase buffer (NEB) 2 µl 2 µl 2 µl 
ddH2O To 20 µl To 20 µl To 20 µl 
Diagnostic digestion reaction was performed with Hind III-HF restriction enzyme and 
incubated at 37°C for 2 hours and digestion reaction was run on 1% agarose gel to select 
correct donor vector.  
Plasmid DNA 1 µg 
Cutsmart Buffer (NEB) 2 µl 
Hind III-HF (20,000 U/ml) (NEB) 0,3 µl 
ddH2O To 20 µl 
 
3.2.4. Cell-Based Reporter Assay Generation 
3.2.4.1. Random gene integration  
To integrate luciferase cassette into HCT 116 WT cells randomly, we used two plasmids 
which are pG13-luc and pSV2-Neo. First, these plasmids were linearized with Pdm I, 
which cut these plasmids inside ampicillin gene, by incubating at 37°C for 2 hours. 
Linearization was controlled in agarose gel and linearized-plasmids were purified by PCR 
clean-up according to manufacturer’s protocol and their concentrations were then 
checked by NanoDrop. Later, linearized-purified plasmids were used for transfection. 
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Given restriction reaction was performed to linearize these plasmids. 
 pG13-luc pSV2-Neo 
DNA 12 µg 6 µg 
Tango Buffer 3 µl 3 µl 
Pdm I (10 U/μl) (Fermentase) 2 µl 1 µl 
ddH2O To 30 µl To 30 µl 
For transfection, 2,5x105 cells were seeded in 6-well plate. On the transfection day, 2 µg 
linearized-pG13-luc plasmid and 1 µg linearized-pSV2-Neo plasmid were mixed in 200 
µl phenol-free serum-free DMEM and then 15 µl PEI (1 µg/µl) was added as considering 
to the molar ratio of 5:1 PEI/DNA and mixture was vortexed immediately. After 15 
minutes incubation at room temperature, the mixture was added dropwise onto the cells. 
In the meantime, to control whether transfection protocol works, another transfection was 
performed with pCDNA3-GFP plasmid. After 48 hours from transfection, transfected 
cells were treated with G418 at 800 ng/µl final concentration for 10-14 days. G418 
resistance colonies were picked up under inverted light microscope and then they were 
analysed to check the integration. 
3.2.4.2. Genome editing with TALENs and donor DNA 
One day before the transfection, 8x105 HCT 116 WT cells were split onto sterile tissue 
culture plate. On the day of the transfection, 5 µg of total plasmid (1 µg TALEN-L, 1 µg 
TALEN-R, and 3 µg AAVS1 SA-2A-puro-pA donor luciferase cassette plasmid) was 
mixed with 1 ml serum-free phenol-free DMEM in a sterile microcentrifuge tube. 25 µl 
PEI (1 µg/µl) was added into DNA-DMEM mix as considering to the molar ratio of 5:1 
PEI/DNA and mixed immediately by vortex. After 15 minutes incubation at room 
temperature, the mixture was added dropwise onto the cells. After 48 hours from 
transfection, puromycin selection was started. Transfected cells were treated with 
puromycin at 1µg/ml concentration for 10-14 days. Subsequently, puromycin resistant 
colonies were picked up under inverted light microscope and then they were analysed to 
determine the integration. 
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3.2.4.3. Analysis of the random and targeted integration 
To examine if the random integration and targeted integration were successful, two 
different approaches were conducted which were polymerase chain reaction (PCR) and 
luciferase assay. While PCR was only performed for targeted integration, luciferase assay 
was applied for both integration methods. 
Polymerase Chain Reaction: To determine the integration of donor DNA into targeted 
locus, three different polymerase chain reactions were performed. PCR with Taq DNA 
Polymerase (NEB) was performed with two different sets of primer to show the 
integration of luciferase cassette into targeted genomic site. Additionally, Phusion High 
Fidelity DNA Polymerase (NEB) reaction was performed with another primer set, which 
includes AAVS-forward and HA-R reverse primer, to show whether integration is 
homozygous or hemizygous.  
We performed the following reaction with either the couple of AAVS-forward and 
Luciferase reverse primers or Luciferase forward and AAVS-reverse primers 
Standard Taq Buffer 2,5 µl 
MgCl2 1,5 µl 
10 mM dNTPs  0,5 µl 
10 µM Forward Primer  0,5 µl 
10 µM Reverse Primer  0,5 µl 
5 M Betaine  5 µl 
Taq DNA Polymerase (5,000 U/ml) (NEB) 0,125 µl 
Genomic DNA 50 ng 
ddH2O To 25 µl 
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Following PCR was performed with the pair of AAVS-forward and HA-R reverse primer.  
5X Phusion GC Rich Buffer 4 µl 
10 mM dNTPs 0,4 µl 
10 µM Forward Primer 1 µl 
10 µM Reverse Primer 1 µl 
Phusion HF DNA Polymerase (2,000 U/ml) NEB 0,2 µl 
Genomic DNA 50 ng 
ddH2O To 20 µl 
Luciferase Assay:  To detect the p53-dependent luciferase expression of the colonies 
which were derived from random integration or targeted integration luciferase assay was 
performed. One day before, all colonies were seeded onto 6-well plate as 2,5x105 cells 
per well. All colonies were treated with doxorubicin at 1 µM concentration for 24 hours. 
Following 24 hours treatment, doxorubicin was removed, and equal number of cells were 
harvested from each colony to perform luciferase assay. To measure the luciferase activity 
of the colonies, 20 µl cell lysate was loaded into Lumitrac 600 96-well plate and then 40 
μl luciferase assay buffer was added onto them. Immediately, luciferase activities of the 
colonies were measured by spectrophotometry.  
3.2.5. The Screening of Compound Library 
3.2.5.1. Compound preparation 
All compounds were dissolved in dimethyl sulfoxide (DMSO) at 100 mM stock 
concentration and stored at – 20 ͦ C. Then, 10 mM working stock was prepared by diluting 
100mM stock in DMSO. All treatment experiments were conducted by using 10 mM 
stock. 
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3.2.5.2. Cell viability assay   
To check the effects of the compounds on cells, MTT assay was used. HCT 116 WT and 
HCT 116 p53-/- cells were treated with compounds at increasing doses (1-5-10 µM) and 
incubated for 48-96 hours, then cell viability was measured with MTT assay according to 
manufacturer’s protocol. DMSO-treated cells were used to normalize the cell viability.  
3.2.5.3. Treatment, cell lysis, and western blotting 
One day before the treatment, cells were seeded as 2,5x105 cells/ well onto 6-well plate 
and then cells were treated with a variety of compounds at certain concentrations and 
incubated for different time intervals. After the treatment, cells were trypsinized and 
counted to prepare cell lysate with equal number of cells for each compound. 5x105-1x106 
cells for each compound were centrifuged at 300 rfc for 5 minutes and then supernatant 
was discarded. The cells were washed with 1 ml 1X PBS and centrifuged at 300 rcf for 5 
minutes to remove 1X PBS. The cell pellets were mixed with appropriate volume of 1X 
PBS and 4X protein loading buffer depending on cell number. The mixture was boiled at 
95°C for 10 minutes. Cell lysates were either used immediately or stored at -80°C for 
later use.  
SDS polyacrylamide gels were prepared depending on the molecular weight of the protein 
of interest. Depending on the interested proteins, either 12,5% separating gel or 10% 
separating gel, and 4% stacking gel were prepared during all western blotting 
experiments. After the preparation of gel and loading of the samples as 20 µl in each well, 
SDS polyacrylamide gels were run with 1X running buffer at 80 V (constant voltage) for 
1.5-2 hours using a BIORAD Mini Protean Tetra Cell. After separation of proteins, SDS 
polyacrylamide gels were transferred to 0.45 µm PVDF transfer membrane (Thermo 
Scientific) in 1X transfer buffer at 250 mA (constant current) for 1-1.5 hours depending 
on the molecular weight of protein at 4°C using BIORAD Mini Trans-blot. After the 
transfer of protein to membrane, membrane was blocked in 10 ml PBST-milk (5% w/v) 
at room temperature for 1 hour by shaking at 25 rpm and then membrane was washed 3-
times with 10 ml PBS-T for 10 minutes each by shaking at 31 rpm. Primary antibody 
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incubations were performed overnight (16 hours) at 4°C with constant shaking and then 
membrane was incubated with secondary antibody which is in PBST-milk (5% w/v) for 
1 hour at room temperature with constant shaking. After incubation with antibodies, same 
washing steps were repeated and then membrane was treated with an enhanced 
chemiluminescent substrate and analysed by using ImageQuantTM LAS4000 
Biomolecular imager.  
3.2.5.4. Screening of the compounds with cell-based reporter assay 
One day before treatment with the compounds, colony 6 was seeded in 24-well plate as 
4x104 cells/ well. The reporter cells were treated with different compounds at a final 
concentration of 1 µM for 72 hours. After the incubation, compounds were removed, and 
cells were washed with 1 ml 1X PBS. Then, 150 µl 1X Passive Lysis Buffer was added 
onto cells in 24-well plate and 24-well plate was shaken at 900 rpm for 20 minutes at 25 
°C for lysis. Cell lysate from each compound was collected into microcentrifuge tubes 
and centrifuged at 1300 rpm for 30 seconds. BCA protein assay was performed according 
to manufacturer’s protocol to measure total protein amount. To measure luciferase 
activity, 20 µl lysate was loaded into Lumitrac 600 96-well plate for each compound and 
40 µl luciferase assay buffer was added onto the cell lysate and immediately luciferase 
activity was measured by spectrophotometry.  
3.2.5.5. Fluorescent two-hybrid assay 
Fluorescent two-hybrid (F2H) assay is microscope-based technique which is used to 
evaluate inhibitors for protein-protein interaction. Principally, in F2H assay tethering 
strategy is applied by using lac operator sequence whose repeats are specifically 
integrated into the genome of modified mammalian cells. Green fluorescence tagged bait 
protein can be localized in lac operator site by using lac I sequence which can specifically 
bind lac operator sequence108. Lac I sequences can either linked to green fluorescence 
protein or can be used as separated system. In separated system green fluorescence 
binding protein (GBP) which is a nanobody is linked to Lac I sequences. Thus, Lac I 
bring GBP to lac operator site, followed by the recruitment of GFP and its tagged bait 
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protein resulted in the formation of green spot.  Red fluorescence tagged prey protein 
binds to bait protein and cause red spot formation109. Finally, co-localization occurs in 
the lac operator site. F2H system enables to visualize the interaction between two partner 
proteins and to screen specific inhibitors which can block this interaction.  
To visualize compound-dependent blocking of the interaction between p53 and MDM2, 
we used F2H assay system according to manufacturer’s protocol and performed live cell 
imaging. In our case p53 protein is tagged with GFP and MDM2 protein is tagged with 
RFP, also another vector produces Lac I linked to GBP. Baby hamster kidney cell line 
(BHK) which has lac operator sequences in its genome is used for F2H assay and live cell 
imaging. To perform F2H assay and live cell imaging, BHK cells were transfected with 
TagGFP-p53, TagRFP-MDM2, and GBP-Lac I plasmids by using PEI as considering to 
3:1 or 4:1 DNA/PEI molar ratio. After 24 hours from transfection, BHK cells were treated 
with various compounds at different concentrations and compound-dependent 
disappearance of the interaction was scanned by In Cell Analyzer (General Electric).  
Given ingredients and required amounts was used for the transfection.  
Ingredients 6-well plate 24-well plate 96-well plate 
TagGFP-p53 1 µg 0,3 µg 0,1 µg 
TagRFP-MDM2 1 µg 0,3 µg 0,1 µg 
GBP-Lac I 1 µg 0,3 µg 0,1 µg 
PEI (1ng/ μl) 9 µg 1,8 µg 1,2 µg 
Serum-free phenol-free 
DMEM 
200 µl 50 µl 20 µl 
BHK cell number 2,5x105 cells/well 5x104 cells/ well 1x104 cells/well 
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4. RESULTS 
 Cell – Based Reporter Assay Generation 
The sequence-specific transcription factor p53 binds to its response element and then 
activates the expression of target genes6. To detect the activity of p53 directly, we 
generated reporter cell lines which can express the luciferase enzyme under the control 
of p53 in a sequence-specific manner. We used two different approaches to integrate a 
luciferase gene into the HCT 116 WT genome: TALEN aided homology-directed repair 
and random integration. For targeted integration, we selected the safe-harbor AAVS1 site 
which is located in intron 1 of the PPP1R12C gene105,106. In the second approach, non-
homologous insertion/transformation ability of these cells was used to integrate the 
luciferase gene randomly into the human cellular genome. Non-homologous insertion 
needs little or no dependence on sequence homology, hence it mostly results in random 
and high copy number integration.  
4.1.1. Donor DNA Construction 
To generate a donor DNA that targets the AAVS1 site, we used a donor vector which 
includes suitable homology arms for the site (Addgene plasmid #22075)110. Because there 
were no suitable restriction sites in the donor vector, we created an intermediate vector 
by integrating p53 binding sequences and a promoter upstream of the luciferase gene. 
First, the pG13-luc plasmid111 was cut with Hind III to obtain a fragment containing the 
p53 binding sequences and the polyoma promoter. The p53 binding sequences and 
polyoma promoter were ligated into the pGL-3-Basic plasmid to create an intermediate 
vector. Insertion was confirmed with diagnostic digestion performed with XhoI cutting 
from the vector and Eco RI cutting from the insert. Colonies with correct oriented inserts 
were selected, because forward-oriented inserts gave a 282 bp digestion product, while 
reverse-oriented inserts gave a 225 bp digestion product. Later, this luciferase cassette 
was removed from the intermediate vector by Xho I and Sal I digestion and cloned into 
Sal I digested AAVS1 SA-2A-puro-pA-donor plasmid. The cloning strategy is shown in 
Figure 4.1.  
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a) 
 
b)  
 
c)                                                                                                          d)                                            
 
Figure 4.1. The donor vector construction. a) Schematic representation of cloning: 
pG13-luc, pGL-3-Basic, and AAVS1 SA-2A-puro-pA-donor plasmid were used to create 
donor DNA. b) Restriction digestion with Xho I and EcoRI to select correct intermediate 
vector. Red arrows show the inserts in the forward orientation. c) Cloning of the luciferase 
cassette into the donor plasmid: Restriction digestion with Hind III displayed that colony 
2 and 18 have the insert (red arrows) in reverse orientation (blue arrows) d) EcoRI 
restriction digestion reconfirmed that colony 2 and 18 have the insert in the reverse 
orientation. V: vector, U: uncut. 
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To confirm the identity of this final plasmid, the diagnostic digestion was carried out with 
Hind III, which has two restriction sites in the vector and two restriction sites inside the 
luciferase cassette. We observed 3 different situations for Hind III digestion: (1) empty 
vector gave 992 bp product- (2) the vector which has forward oriented luciferase cassette 
gave 465 bp, 1001 bp, 1969 bp, and 5610 bp products and- (3) the vector which has 
reverse-oriented luciferase cassette gave 33 bp, 465 bp, 2937 bp, and 5610 bp products. 
We obtained two colonies which contain the luciferase cassette in the desired, reverse 
orientation. Additionally, these two colonies were re-confirmed with Eco RI digestion. 
These digestions showed that both have the correct insert the in reverse orientation. 
Therefore, colony 2 was selected as a template DNA for the generation of reporter cell 
lines (Figure 4.1c-d). We wanted to insert the luciferase expression cassette in the reverse 
orientation into the AAVS site because we did not want to interfere with the PPP1R12C 
gene expression. 
4.1.2. Luciferase Cassette Integration by TALENs and HDR 
The AAVS1 site which is mostly used for the integration by adeno-associated viruses was 
chosen to integrate the luciferase cassette. This site provides long-term expression for 
integrated genes106. We used two plasmid that were previously developed that encode a 
pair of TALEN proteins targeting AAVS1 site (Addgene numbers #35431 and #35432)92. 
To integrate the luciferase cassette into this site, HCT 116 WT cells were transfected with 
three plasmids encoding the Left-TALEN, the Right-TALEN, and the AAVS1 SA-2A-
puro-pA-donor luciferase cassette. First, double-strand break was formed specifically in 
this site by TALENs. Subsequently, the created double-strand break was repaired by the 
cells with either HDR or NHEJ. The AAVS1 SA-2A-puro-pA-donor luciferase cassette 
plasmid was used by the cells as a template to repair the break by HDR. This plasmid 
contained homology arms for the integration into the AAVS1 by HDR. The sequences 
between two the homology arms were integrated into this site via HDR (Figure 4.2). 
Transfected cells were treated with 1 µg/ml puromycin to select the cells having 
integration. Because the puromycin gene is located between these two homology arms. 
In the case of puromycin integration into this site, the cells start to express puromycin 
under the control of an endogenous promoter and become puromycin resistant.  
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In addition to using puromycin for selection, it might be used an indicator of specific 
integration because the puromycin gene does not contain any promoter. Thus, its 
expression is regulated by the promoter of PPP1R12C gene only after homologous 
integration. After puromycin treatment for 10-14 days, puromycin positive cells formed 
individual colonies. These colonies were picked up and grown individually. Later, these 
colonies were analyzed with the polymerase chain reaction method to show specific 
luciferase cassette integration and luciferase assay was performed to confirm the 
functionality of the cell-based reporter assay.  
a) 
 
b) 
 
Figure 4.2. Schematic representation of luciferase cassette integration by TALENs 
and HDR. a) TALENs work as a pair. When right TALEN and left TALEN bind to the 
target sequence in intron 1 of PPP1R12C gene specifically Fok I can cleave DNA from 
both strands and create the double-strand break. b) Luciferase cassette integration into the 
AAVS1 site through HDR.  
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4.1.2.1. Analysis of the integration with polymerase chain reaction 
We conducted three different polymerase chain reaction experiments to determine 
whether the integration of the donor construct was homozygous or hemizygous. We 
designed five primers: while two of them bind to intron 1 of the PPP1R12C gene without 
binding to donor DNA, other two primers only bind to the luciferase gene (Figure 4.3a). 
The last primer can bind to both intron 1 and the luciferase cassette. The pair of AAVs-
forward primer and luciferase-reverse primer and the pair of luciferase forward primer 
and AAVs-reverse primer were used to conclusively demonstrate the presence of targeted 
integration (Figure 4.3b-c). Additionally, we carried out another PCR with a pair of 
AAVs-forward and HA-R reverse primers to determine whether the integration was 
hemizygous. Because the pair of AAVs-forward and HA-R reverse primer gives a 
specific product for wild-type genome. PCR results showed that most of the colonies have 
luciferase cassette integration in just one allele. However, some colonies did not give any 
products for both wild-type genome and luciferase cassette in the PCR with AAVs-
forward and HA-R reverse primer. These colonies were determined to contain the 
insertion in both alleles (Figure 4.3d).  
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b) c)
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Figure 4.3. Analysis of the integration by polymerase chain reaction. a) Binding sites 
of the primers were shown. b) PCR was carried with the pair of AAVS-forward and 
luciferase reverse primer. Most of the colonies gave 2.4 kb PCR product because of 
insertion. c) PCR was conducted with the pair of luciferase-forward and AAVS-reverse 
primer. PCR product in 1.5 kb length showed successful integration. d) PCR was 
conducted with a couple of AAVS-forward and HA-R reverse primers. While 1.7 kb (red 
arrow) PCR product indicated wild-type allele, 4.7 kb (red arrow) band showed that 
luciferase cassette integration. 
4.1.2.2. Detection of the functionality of the reporter cell lines 
After the determination of luciferase cassette integration into the genome, the next step 
was the evaluation of the functionality of the reporter cell lines. In this reporter system, 
luciferase expression is controlled by p53. In detail, 13 consecutively repeated p53 
binding sites act as an enhancer to activate the polyoma promoter driving luciferase 
expression. Therefore, we checked if the system works when p53 is activated by DNA 
damage in these cells. For this purpose, the p53-dependent luciferase activities of colonies 
were evaluated by a luciferase reporter assay after doxorubicin treatment. Doxorubicin 
increases p53 level in cells by causing DNA damage112. In the presence of DNA damage, 
p53 is activated by several kinases and then p53 translocate into the nucleus. The 
translocation of p53 into the nucleus initiates the expression of p53 target genes7. 
WT         15       18         21          22          23         24           28         30         31
1         2        5           8        9       10       11       12       13      14       16       17
19    20      25     27      32       33      34       35     36       37      38       39    41
42        43       44        45     46     3       4         6          7           26         29           
d)
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Puromycin resistant 47 colonies were treated with 1 µM doxorubicin for 24 hours and 
their luciferase activity were measured by luciferase assay (Figure 4.4). We observed 
three different patterns in luciferase activity of the colonies: (1) 22 colonies showed very 
low luciferase activity, (2) 18 colonies showed moderate luciferase activity, (3) 7 colonies 
showed high luciferase activity. In accordance with luciferase assay results, these 7 
colonies (colony 3-4-6-7-26-29-46) were selected for further analysis.   
 
 
Figure 4.4. Validation of cell-based reporter system by luciferase assay. Puromycin 
resistance 47 colonies were expanded and their p53 dependent luciferase activities were 
analyzed under 1 µM doxorubicin treatment for 24 hours. Luciferase activities of the 
colonies were calculated by subtracting their background luciferase activities from their 
total luciferase activities.  
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Further, to make a more specific analysis about p53-dependent activation of luciferase 
expression, the selected colonies were treated with 10 µM Nutlin-3a for 24 hours which 
activates p53 by blocking the interaction between p53 and MDM265. In the meantime, 
selected colonies were separately treated with 1 µM doxorubicin for 24 hours to elucidate 
the consistency of these reporter cell lines and to compare the doxorubicin response with 
Nutlin-3a (Figure 4.5). As expected, Nutlin-3a responses of the colonies were lower than 
their doxorubicin response except colony 29. Nutlin-3a only blocks the p53-MDM2 
interaction without changing the p53 mRNA level and without initiating damage 
signaling.  
 
Figure 4.5. Comparison of luciferase responses of doxorubicin and Nutlin-3a. The 
selected colonies were treated with 1 µM doxorubicin and 10 µM Nutlin-3a for 24 hours 
separately. Luciferase activities of the colonies were measured by luciferase assay. 
Luciferase activities of the colonies were calculated by subtracting their background 
luciferase activities from their total luciferase activities. 
Moreover, time-dependent luciferase activities of the selected seven colonies were 
measured with a time-course experiment. Selected colonies were treated with 1 µM 
doxorubicin for 0, 2, 6, 12, 18, 24 hours respectively and luciferase activities of these 
colonies were measured by luciferase assay (Figure 4.6).  
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Figure 4.6. Analysis of time-dependent luciferase activity. Selected colonies were 
treated with 1 µM doxorubicin at increasing times (0,2,6,12,18,24 hours) and their 
luciferase activities were measured. Luciferase activities of the colonies were calculated 
by subtracting their background luciferase activities from their total luciferase activities. 
Due to fact that colony 6 responded to doxorubicin and to Nutlin-3a treatment with very 
high luciferase activity and the expected difference between doxorubicin and Nutlin-3a 
response was observed and a time-dependent response was observed, colony 6 was 
selected to evaluate the effect of a variety of compounds on the transcriptional activity of 
p53. 
4.1.3. Cell-Based Reporter Assay Generation by Random Integration 
HCT 116 WT cells were also cotransfected with a luciferase cassette containing pG13-
luc plasmid and a neomycin cassette containing pSV2-Neo plasmid for selection. Because 
this luciferase cassette plasmid does not contain any selection marker, a second plasmid 
was required for selection. After transfection, these cells were subjected to G418 
treatment at 800 ng/ml final concentration for 10-14 days to select the cells which have 
neomycin gene integration. We assumed that if the neomycin gene was integrated into 
the genome, luciferase cassette could also be integrated into the genome. Therefore, we 
picked up 26 neomycin resistant colonies and grew them individually to analyze the 
luciferase cassette integration by luciferase assay (Figure 4.7).  
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Figure 4.7. Cell-based reporter assay generation through random integration. HCT 
116 WT cells were transfected with pG13-luc and pSV2-Neo. Neomycin selection, 
colony pick, and luciferase assay were performed respectively. Luciferase activity of the 
colonies was evaluated with luciferase assay.   
4.1.3.1. Evaluation of the random integration by luciferase assay 
Neomycin resistant colonies were treated with 1 µM doxorubicin for 24 hours and 
subsequently, their luciferase activities were measured by spectrophotometry. 3 out of 26 
colonies showed higher luciferase activity than the baseline determined by using extract 
from untreated (Figure 4.8). Nutlin-3a responses of these three colonies (8- 19 and 24) 
were also examined under 10 µM Nutlin-3a treatment for 24 hours (Figure 4.9). 
Additionally, these colonies (8- 19 and 24) were treated with 1 µM doxorubicin for 0, 2, 
6, 12, 18, and 24 hours respectively and their luciferase activities were measured. As a 
result, colony 8, 19, and 24 showed lower luciferase activity after treatment with Nutlin-
3a compared to treatment with doxorubicin as expected. Moreover, the time-course 
responses of these colonies showed that the highest luciferase activity was detected after 
18 hours for colony 8 and 24 was detected after 18 hours treatment, while it was detected 
after 12 hours treatment for colony 19 (Figure 4.10).  
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Figure 4.8. Validation of cell-based reporter system generated by random 
integration. Neomycin positive colonies were expanded, and their p53-dependent 
luciferase activities were analyzed under 1 µM doxorubicin treatment for 24 hours. 
Luciferase activities of the colonies were calculated by subtracting their background 
luciferase activities from their total luciferase activities. 
 
Figure 4.9. Nutlin-3a-dependent luciferase activity of the colonies. The selected 
colonies were treated with 10 µM Nutlin-3a for 24 hours. Luciferase activities of the 
colonies were detected with luciferase assay. Luciferase activities of the colonies were 
calculated as subtracting their background luciferase activities from their total luciferase 
activities. 
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Figure 4.10. Time-dependent luciferase activity of the colonies. Selected colonies 
were treated with 1 µM doxorubicin at increasing times (0,2,6,12,18,24 hours) and their 
luciferase activities were measured. Luciferase activities of the colonies were calculated 
by subtracting their background luciferase activities from their total luciferase activities. 
 The Screening of Novel Compounds 
We wanted to screen a novel small molecule compound library generated in collaboration 
with Prof. Burak Erman from Koc University and Prof. Nilgün Karali from Istanbul 
University, which contains nearly one hundred small molecules. All compounds were 
screened to identify a small molecule that can activate p53 without causing DNA damage 
in wild-type p53 carrying cells. For this purpose, we conducted a variety of experiments. 
The effects of the compounds on p53 accumulation, activation, and phosphorylation were 
investigated by using different methods. The p53 protein has a very short half-life in the 
absence of any kind of stimulus that can stabilize p537. The p53 protein can be activated 
by either specifically blocking its interaction with MDM265 or by DNA damage112. To 
check compound-dependent p53 accumulation and phosphorylation in HCT 116 WT 
cells, we performed several western blotting experiments. We used our cell-based 
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luciferase reporter assay to evaluate if accumulated p53 is transcriptionally active in these 
cells. Moreover, we analyzed the effect of the compounds on the induction of double-
strand breaks through western blotting and we also checked the viability of HCT 116 WT 
and HCT 116 p53-/- cells by an MTT assay to determine the impact of p53 on cell death.  
4.2.1. Effects of The Compounds on Cell Viability 
One of the roles of p53 is to regulate apoptosis by activating the expression of pro-
apoptotic genes10. Thus, p53 activation can cause cell death in some circumstances, such 
as severe DNA damage.  To explore the effects of the compounds on cell viability, we 
performed an MTT assay. We used two cell lines which were HCT 116 WT and HCT 
116 p53-/- to determine whether these effect of compounds on cell viability is p53-
dependent. We used HCT 116 p53-/- cells as a negative control to possibly show that the 
effect of the compounds on cell viability is p53-dependent. In such a case, the viability of 
these cells should not be affected. To compare the MTT assay results of the compounds, 
Nulin-3a was chosen as positive control, because of its specificity towards p53-sufficient 
cells. In the presence of wild-type p53, Nutlin-3a decreased cell viability as correlated 
with increasing doses, whilst Nutlin-3a did not decrease cell viability in the absence of 
p53 (Figure 4.11).  
 
Figure 4.11. Cell viability assay with Nutlin-3a. HCT 116 WT and HCT 116 p53-/- 
cells were treated with Nutlin-3a at increasing doses (0-1-5-10 µM) respectively for 72 
hours and then MTT assay was performed. Result was presented by normalizing to the 
viability of DMSO treated cells.  
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Figure 4.12. The effect of the compounds on cell viability. HCT 116 WT and HCT 116 
p53-/- cells were treated with several compounds at increasing doses (1-5-10 µM) 
respectively for 48 hours and then MTT assay was performed. The results were presented 
by normalizing to the viability of DMSO treated cells. 
We observed that compared to Nutlin-3a, all tested compounds caused a decrease in cell 
viability in both p53-deficient and sufficient cell lines (Figure 4.12). This result indicates 
that these compounds at these doses do not show any specificity in inhibiting the 
interaction between p53 and MDM2.    
4.2.2. Detection of Compound-Dependent p53 Accumulation / Phosphorylation 
and DNA Damage  
In the absence of stress or any p53 inducing agents, p53 protein level cannot be detected 
by western blotting due to its short half-life. If the cells are exposed to any DNA damaging 
agents or specific inhibitors, that prevent the interaction between p53 and MDM2, the 
p53 protein level can be detected with western blotting. To investigate the impact of the 
compounds on the p53 protein and DNA damage formation, we conducted three different 
western blotting experiments. First, we evaluated the p53 protein level after the treatment 
with various compounds by western blotting (Figure 4.13). For this purpose, HCT 116 
WT cells were treated with a variety of compounds at a concentration of 10 µM for 48 
hours and p53 protein levels were detected in whole cell lysates by western blotting. The 
effect of each of the compounds on p53 protein levels was compared with the effect of 
compound D71, which was used as positive control. The compound D71 was previously 
identified as a candidate molecule that interferes with the interaction between p53 and 
MDM2. Every compound induced the accumulation of the p53 protein in HCT 116 WT 
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cells at different levels. As a result, many compounds which increased the p53 protein 
level more than D71 were selected as candidate compound and they were then subjected 
to DNA damage analysis.  
 
Figure 4.13. The accumulation of the p53 protein. HCT 116 WT cells were treated 
with a variety of compounds at 10 µM concentration for 48 hours and then the 
accumulation of the p53 protein (53 kDa) was analyzed in the whole cell lysates. 
UT/DMSO: negative control, D71: positive control.  
In the second part of western blotting, selected compounds were evaluated in terms of 
their influence on DNA damage by phospho-H2A.X western blotting. H2A.X is a histone 
variant protein and is phosphorylated in the presence of DNA damage and binds to 
double-strand breaks on DNA113. The increase in the phosphorylated-H2A.X level 
indicates the occurrence of double-strand breaks. The phosphorylated-H2A.X level is also 
increased by apoptosis-dependent DNA fragmentation114. Like in p53 western blotting, 
whole cell lysates were prepared after the treatment of HCT 116 WT cells with selected 
compounds and phospho-H2A.X levels of the selected compounds were determined with 
a specific antibody. For phospho-H2A.X western blotting, doxorubicin and D71 were 
used as positive control, Nutlin-3a and DMSO were used as negative control. Phospho-
H2A.X western blotting results indicated that all compounds led to significant double-
strand break formation at different levels (Figure 4.14).  
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Figure 4.14. Analysis of the double-strand break formation by phospho-H2A.X. 
HCT 116 WT cells were treated with various compounds at 10 µM concentration for 48 
hours and then phosphorylated-H2A.X (15 kDa) level was evaluated in the whole cell 
lysate. DMSO: negative control, D71 and Doxorubicin (was used at 1 µM concentration): 
positive control.  
To evaluate if the compounds were activating p53 through DNA damage signaling, HCT 
116 WT cells again treated with selected compounds and then harvested to check 
phospho-p53 protein level. Because phosphorylated-p53 on serine 15 is an indicator of 
damage-dependent activation of p53115. Therefore, western blot results indicated that 
selected compounds caused p53 phosphorylation at different levels (Figure 4.15). While 
Nutlin-3a was used as negative control, doxorubicin was used positive control for the 
phosphorylation of p53 in serine 15 residue.  
Our aim in these experiments was to find a compound that increases cellular p53 levels 
by inhibiting the interaction between MDM2 and p53, without causing significant DNA 
damage. Unfortunately, all compounds showed at least some kind of DNA damage 
dependent signaling. These findings indicate that we need to increase the library size of 
the molecules being screened in future experiments.  
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Figure 4.15. Investigation of p53 phosphorylation. HCT 116 WT cells were treated 
with selected compounds at 10 µM concentration for 48 hours. Afterwards, phosho-p53 
level was checked in the whole cell lysate for each compound. DMSO/Nutlin-3a: negative 
control, D71 and doxorubicin (was used at 1 µM concentration): positive control.  
4.2.3. Analysis of Compound-Dependent Changes in p53 Activity  
The effect of the compounds on p53 activity was probed through cell-based reporter 
assay. The small molecule compound library was tested to identify those that cause p53 
nuclear translocation and transcriptional activation. The reporter cell line which was 
generated in the first part of the study was treated with various compounds at 1 µM final 
concentration for 72 hours and then the changes in the luciferase activity were measured 
for each compound (Figure 4.16). Total protein amounts in lysates were used to normalize 
luciferase activity. Cell-based reporter assay results indicated that many compounds 
showed the same luciferase activity with untreated cells or less luciferase activity than 
the untreated cells and a few compounds increased the luciferase activity. In order to show 
that the cell-based reporter assay was working, Nutlin-3a was used as positive control. 
For this purpose, the reporter cell line was treated with Nutlin-3a at 10 µM concentration 
for 24 hours. As a result of the initial screen of all compounds, 22 compounds that yield 
high luciferase values were selected to reproduce these results. As a result, we found that 
11 compounds reproducibly increased luciferase expression compared to untreated cells 
(Figure 4.17).   
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Figure 4.16. Screening of the compounds by cell-based reporter assay. Reporter cell 
line was treated with a variety of compounds at 1 µM final concentration for 72 hours. 
Compound-dependent luciferase activity was normalized to protein amount. The changes 
in luciferase activity were shown by normalizing to untreated cells’ luciferase activity. 
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Figure 4.17. Cell-based reporter assay with selected compounds. (a) Reporter cell line 
was treated with Nutlin-3a at 10 µM final concentration for 24 hours as a positive control. 
(b) Reporter cell line was treated with the selected compounds at 1 µM final concentration 
for 72 hours as triplicate. This experiment was repeated twice, and results were presented 
as taking the average of two experiments. Luciferase activity was calculated by 
normalizing to the total protein amount and then the changes in luciferase activity were 
shown by normalizing to untreated cells’ luciferase activity. 
4.2.4. Effect of The Compounds on MDM2- p53 Interaction 
11 compounds which activated p53 in reporter assays were tested by the F2H assay 
combined with the live cell imaging technique to explore if this activation is related with 
the blocking of the interaction between MDM2 and p53. The BHK cell line containing 
tandem repeats of lac operator sequences inserted into its genome, was transfected with 
F2H assay’s plasmids encoding LacI-GBP, GFP-p53, and RFP-MDM2 fusion proteins. 
24 hours after transfection, the cells were treated with the compounds at 10 µM 
concentration and live cell imaging was performed immediately for 3 hours by In Cell 
Analyzer 2500 HS microscope. Nutlin-3a, which block the MDM2-p53 interaction, was 
used to check if all steps of the F2H assay and live cell imaging were working correctly. 
We clearly observed that Nutlin-3a rapidly reduced both the number of red (MDM2) and 
yellow foci (MDM2-p53 interaction) without affecting the number of green foci (p53) 
(Figure 4.18a). The decrease in yellow foci indicates the inhibition of the MDM2-p53 
interaction. The green foci do not significantly change because the interaction between 
p53 and lac operator site is stabilized using a GFP binding nanobody protein fused to the 
lacI transcription factor. This nanobody is specific for GFP and does not bind to RFP 
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which fused to the MDM2 protein. As a result, we showed that F2H assay coupled with 
live cell imaging method can be used to analyze the effect of the compounds on MDM2-
p53 interaction.  
Selected compounds were analyzed with the same approach to identify those that could 
disrupt the interaction between p53 and MDM2 (Figure 4.18b).  We used this assay to 
specifically identify compounds that inhibit the interaction between p53 and MDM2 
without causing DNA damage. D71 was used as negative control because even though it 
elevated p53 protein levels by western blotting, it also caused DNA damage as indicated 
by phospho-H2AX western blotting. Moreover, it did not increase the transcriptional 
activity of p53 in the luciferase assay. Consequently, whilst Nutlin-3a caused a significant 
decrease in the interaction between MDM2 and p53 in the F2H assay, all tested 
compounds failed to cause any significant changes in the interaction. Foci counting and 
data analysis was performed using the IN Cell Developer Software by General Electric. 
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Figure 4.18. Analysis of the blocking of MDM2-p53 interaction. The combination of 
F2H assay and live cell imaging method was used to analyze compound-dependent 
disruption of MDM2-p53 interaction. a) Nutlin-3a was used as positive control for F2H 
assay. b) 11 compounds were tested by F2H assay to check their effect on the interaction. 
Green line: p53, red line: MDM2, yellow line: merge of p53 and MDM2. 
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5. DISCUSSION 
The sequence-specific transcription factor p53 activates the expression of various genes 
and regulates important cellular processes, such as apoptosis and cell cycle arrest1. 
Because of its diverse functions, the perturbations in the regulation of p53 and the 
mutations in the TP53 gene are mostly associated with tumor development and 
progression22,56. p53 is strictly regulated by MDM2 through a negative feedback loop27. 
Normally, p53 is bound to the N-terminal domain of MDM2 from its transactivation 
domain and it is rapidly degraded by the 26S proteasome in a ubiquitination-dependent 
fashion. In the case of genotoxic stress, the p53 protein is activated by posttranslational 
modifications and translocate into the nucleus33,35.  
We generated reporter cell lines to probe the changes in the transcriptional activity of p53. 
We utilized genome editing tools to create reporter cell lines. First, we constructed a 
donor DNA which includes suitable homology arms matching with the AAVS1 target site 
for homologous integration, a puromycin gene for selection, and a luciferase cassette. The 
reason for the selection of luciferase as a reporter gene is its sensitivity, high dynamic 
range and ease of quantification. As noted in the result section, we designed the donor 
DNA construct to insert the luciferase cassette in a reverse orientation with respect to the 
PPPR1C12 gene into which we inserted this cassette by homologous recombination. This 
design was important as transcription in the same orientation as the PPPR1C12 gene 
could potentially interfere with its expression. On the other hand, transcription in the 
reverse orientation creates a situation where complementary double strand may form, but 
we did not detect any such inhibitory effect. In this system, the endogenous promoter only 
controlled the expression of the puromycin selection gene which did not have any 
promoter in the donor DNA. The endogenous promoter-induced puromycin gene 
expression was also used as an indicator for the site-specific insertion. We confirmed the 
luciferase cassette integration into the targeted site by using polymerase chain reaction 
and checked that if the reporter system was working efficiently by luciferase assay. p53-
induced changes in the luciferase activity of the reporter cell lines were confirmed under 
doxorubicin and Nutlin-3a treatments. We found that most of the integrations occurred in 
only one allele. This might result because of the inefficiency of TALENs and the 
homology-directed repair mechanism. We also demonstrated that several colonies 
64 
 
contained insertion in two alleles. There are significant differences of the luciferase 
activity of hemizygous and homozygous colonies. This diversity might be created by the 
differences in the transcriptional activity of p53 in the different clones. Another reason 
for this variability may be the epigenetic modification of the promoter of the luciferase 
gene, such as methylation. Nevertheless, we obtained several colonies which can produce 
a significant luciferase response against doxorubicin and Nutlin-3a treatment in a stable 
and reproducible manner.   
This study allowed us to compare reporter genes generated by insertion into a targeted 
safe harbor site as well as the traditional stable transfection approach. Using the second 
approach, we only obtained three colonies which showed significant luciferase activity 
depending on the activation of p53. Despite having a high integration copy number, these 
colonies expressed less luciferase compared to the safe harbor site integrated clones. This 
difference in transcriptional activity may be integration site dependent. Random 
integration can occur in almost everywhere the genome. However, every region in the 
genome does not equally activate gene expression. Additionally, there was a minor 
difference in the sequence of these two luciferase genes. This discrepancy might affect 
the luciferase enzyme's affinity towards its substrate and its speed of catalysis.  
We screened numerous compounds to identify their effect on cell viability, the cellular 
levels of p53 protein, and DNA damage formation. We found that almost every compound 
causes a decrease in cell viability at different levels regardless of p53. Cell viability assay 
results showed that the compounds might have some side effects, thus causing cell death 
independent from p53. We obtained important results with respect to the impact of the 
compounds on p53. In the first instance, we found that each compound can induce the 
accumulation of p53 at varying degrees in HCT 116 WT cells. We can explain the cause 
of p53 accumulation with two different approaches: (1) the compounds might increase 
the stability of p53 by posttranslational modifications. (2) the compounds might block the 
interaction between MDM2 and p53 by binding to either MDM2 or p53. As a second 
result related with the p53 protein, we found that all tested compounds induce 
phosphorylation of p53 on serine 15 residue. This phosphorylation is mostly governed by 
ATM signaling and results in the stabilization of the p53 protein33. Compound-induced 
specific phosphorylation of the p53 protein showed that the compounds might activate 
stress signaling which causes the stabilization of p53. Unfortunately, all compounds 
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tested cause DNA damage and induce double-strand breaks. The compounds likely cause 
DNA damage by using several mechanisms, such as intercalating into DNA double 
helices, inhibiting topoisomerase II and cross-linking with DNA strands.  
We also answered the following question: Is stabilized p53 transcriptionally active? To 
answer this question, we created a cell-based reporter assay. Reporter cell line was treated 
with the compounds and then the changes in luciferase activity were measured. We found 
that while some compounds could bring p53 to transcriptionally active state, some of 
them did not change luciferase activity or caused a decrease in luciferase activity. The 
reason for the decrease might the binding of the compounds to p53 irreversibly or the 
inhibition of some posttranslational modifications of p53 which might be required for 
passing p53 from transcriptionally inactive state to active state. These differences may be 
identified by performing RNAseq to differentiate between pathways that are activated by 
different compounds. 
In this study, we also investigated whether the compounds inhibit the MDM2-p53 
interaction. Considering the live-cell imaging results, we showed that the compounds 
cannot dissociate p53 from MDM2, although they can increase p53-dependent luciferase 
activity in the cell-based reporter assay. We can explain this situation by postulating that 
the compounds have a lower affinity against MDM2 than p53 has. This may result in the 
failed dissociation of p53 and MDM2 in this experimental condition. As a second 
explanation of the inability of the compounds to dissociate p53-MDM2 while activating 
p53 reporters, may be the use of alternative pathways or an issue with sensitivity.  
In conclusion, we showed that homology-directed repair mechanism can be used to 
integrate a gene of interest into the targeted site with the help of programmable nucleases. 
We also confirmed that cell-based reporter assay is an efficient method to probe p53 
activity. Additionally, we evaluated several compounds in respect of their influence on 
the cell viability, the p53 protein, DNA damage, and protein-protein interaction. 
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The compound screening was performed by using six different methods and all screening 
results were summarized in Table 5.1.  
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Table 5.1.Summary of the results of screened compounds. Luc assay: p53 activation 
analysis, p53: p53 accumulation analysis, p-H2AX: DNA damage analysis, p-p53: 
analysis of p53 phosphorylation, and F2H: MDM2-p53 interaction analysis, MTT: cell 
viability analysis. In the MTT, positive result means that cell viability was decreased in 
both p53-sufficient and deficient cells. +: positive result, -: negative result, and ND: not 
determined. 
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7. APPENDICES 
APPENDIX A – Chemicals 
Chemicals and Media Components Supplier Company 
2-Mercaptoethanol Sigma, Germany 
Acetic acid (glacial) Merck Millipore, USA 
Acrylamide/ Bis-acrylamide Sigma, Germany 
Agarose Sigma, Germany 
Ammonium Persulfate Sigma, Germany 
Ampicillin Sodium Salt Cellgro, USA 
Betaine Sigma, Germany 
Boric Acid Molekula France 
Bromophenol Blue Sigma, Germany 
Calcium Chloride Sigma, Germany 
D-Glucose Sigma, Germany 
Distilled Water Merck Millipore, USA 
DMEM Thermo Fisher Scientific, USA 
DMEM Phenol Red Free  Thermo Fisher Scientific, USA 
DMSO Sigma, Germany 
DNA Gel Loading Dye, 6X NEB, USA 
Doxorubicin Hydrochloride Sigma, Germany 
EDTA Sigma, Germany 
Ethanol Sigma, Germany 
Ethidium Bromide Sigma, Germany 
Fetal Bovine Serum Thermo Fisher Scientific, USA 
Glycerol Sigma, Germany 
Glycine Sigma, Germany 
Hydrochloric Acid Sigma, Germany 
Hydrogen Peroxide Sigma, Germany 
Isopropanol Sigma, Germany 
Kanamycin Sulphate Thermo Fisher Scientific, USA 
LB Agar Sigma, Germany 
LB Broth Invitrogen, USA 
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Liquid Nitrogen Karbogaz, Turkey 
Luminol Sigma, Germany 
Methanol Sigma, Germany 
Nutlin-3a Sigma, Germany / MCE, USA 
PBS Thermo Fisher Scientific, USA 
p-Coumaric Acid Sigma, Germany 
Penicillin/Streptomycin Thermo Fisher Scientific, USA 
pH4.0 Buffer Solution Merck Millipore, USA 
pH7.0 Buffer Solution Merck Millipore, USA 
PIPES Sigma, Germany 
Polyethyleneimine  Polysciences, USA 
Potassium Acetate Merck Millipore, USA 
Potassium Chloride Sigma, Germany 
Puromycin Dihydrochloride Sigma, Germany 
RNase A Roche, Germany 
SDS Sigma, Germany 
Skim Milk Powder Sigma, Germany 
Sodium Azide Amresco, USA 
Sodium Chloride Amresco, USA 
Sodium Hydroxide Sigma, Germany 
TEMED Applichem, Germany 
Tris Base Sigma, Germany 
Tris Hydrochloride Amresco, USA 
Trypan Blue Solution Thermo Fisher Scientific 
Tween-20 Sigma, Germany 
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APPENDIX B – Equipment 
Equipment Supplier Company 
Autoclave HiClave HV-110, Hirayama, Japan 
Balance Isolab, Germany                           
Sartorius, Germany 
Biomolecular Imager ImageQuant LAS 4000 mini – GE 
Healthcare, USA 
Centrifuge 5418R, Eppendorf, Germany 
5702, Eppendorf, Germany 
5415R Eppendorf, Germany 
Allegra X-15R, Beckman Coulter, USA 
CO2 Incubator Binder, Germany 
Countless II Automated Cell Counter Thermo Fisher Scientific, USA 
Deepfreeze -80, Forma 88000 Series, Thermo Fisher 
Scientific, USA 
-20, Bosch, Germany 
Distilled Water Millipore, Elix – S, France 
Electrophoresis Apparatus VWR, USA 
  
Filters (0.22 Pm and 0.45 Pm) Merck Millipore, USA 
Freezing Container Mr. Frosty, Thermo Fisher Scientific, 
USA 
Gel Documentation Gel Doc EZ, Biorad, USA  
Heater Thermomixer Comfort, Eppendorf, 
Germany 
Hemocytometer Neubauer Improved, Isolab, Germany 
Ice Machine AF20, Scotsman Inc., USA 
Incubator BE300, Memmert, Germany 
Incubator Shaker Innova 44, New Brunswick Scientific, 
USA,                                            
Heidolph Titramax 1000,Heidolph, 
Germany 
Laminar Flow HeraSafe HS15, Heraeus, Germany 
HeraSafe HS12, Heraeus, Germany 
Liquid Nitrogen Tank Taylor-Wharton, 300RS, USA 
Magnetic Stirrer SB162, Stuart, UK 
Microliter Pipettes Thermo Fisher Scientific, USA 
79 
 
Microplate Reader iMark Reader, Bio-Rad, USA          
Model 680, Bio-Rad, USA                     
Microscope Primovert, Zeiss, Germany  
CK40, Olympus, Japan 
IN Cell Analyzer, General Electric, USA 
Microwave Oven Bosch, Germany 
pH Meter SevenCompact, Mettler Toledo, USA 
Power Supply Biorad, PowerPac 300, USA 
Refrigerator Bosch, Germany 
Arcelik, Turkey 
Panasonic, Japan 
Spectrophotometer Fluoroskan Ascent FL, Thermo Fisher 
Scientific, USA 
NanoDrop 2000, Thermo Fisher 
Scientific, USA 
Ultrospec 2100 pro, Amersham 
Biosciences, UK 
Thermal Cycler C1000 Touch, Biorad, USA 
PTC-200, MJ Research Inc., Canada 
Vortex VWR, USA 
Water Bath Innova 3100, New Brunswick Scientific, 
USA  
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APPENDIX C – Molecular Biology Kits 
Commercial Kit Supplier Company 
Cell Proliferation Kit I (MTT) Roche, Switzerland 
Dual Luciferase Reporter Assay System Promega, USA 
F2H®-Kits p53-Mdm2/4 ChromoTek, USA 
GenElute Agarose Spin Columns Sigma-Aldrich, USA 
Luciferase Assay System Promega, USA 
Multisource Genomic DNA Miniprep Kit Axygen, USA 
NuceloSpin Gel and PCR Clean-up Macherey-Nagel, USA 
PierceTM BCA Protein Assay Kit Thermo Fisher Scientific, USA 
PureLink Genomic DNA Mini Kit Invitrogen, USA 
PureLink HiPure Plasmid Midiprep Kit Invitrogen, USA 
PureLink Quick Gel Extraction Kit Invitrogen, USA 
ZymoPure Plasmid Maxiprep Kit Zymo Research, USA 
 
APPENDIX D – Antibodies 
Antibody Supplier Company Catalog Number 
P53 (1C12) Mouse  Cell Signaling Technology 2524S 
p-p53 (S15) (16G8) Mouse  Cell Signaling Technology 9286P 
P53 Rabbit Ab Cell Signaling Technology 9282S 
p-Histone H2A.x (S139) 
(20E) Rabbit 
Cell Signaling Technology 9718S 
Beta-Actin Rabbit Cell Signaling Technology 4967L 
Anti-rabbit IgG HRP-linked  Cell Signaling Technology 7074S 
Anti-mouse IgG Peroxidase Sigma A9044 
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APPENDIX E – DNA Molecular Weight Marker 
 
Figure E.1. Thermo Scientific GeneRuler DNA Ladder Mix (SM0331) 
 
Figure E.2. New England BioLabs 2-Log DNA Ladder (N3200S) 
82 
 
 
Figure E.3. New England BioLabs Color Prestained Protein Standard, Broad 
Range (11–245 kDa) (P7712S) 
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APPENDİX F – Plasmid Maps 
 
Figure F.4. The plasmid map of pUC19 
 
Figure F.5. The plasmid map of pcDNA3-GFP 
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Figure F.6. The plasmid map of pSV2-Neo 
 
Figure F.7. The plasmid map of pG13-luc 
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Figure F.8. The plasmid map of pGl3-Basic 
 
Figure F.9. The plasmid map of intermediate vector 
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Figure F.10. The plasmid map of AAVS1 SA-2A-puro-pA donor 
 
Figure F.11. The plasmid map of AAVS1 SA-2A-puro-pA donor-luciferase cassette  
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Figure F.12. The plasmid map of hAAVS1 1L TALEN 
 
Figure F.13. The plasmid map of hAAVS1 1R TALEN 
 
